STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 192668

TO:	From:
Devesh Khare Location: 5c35 / 5c18 Wednesday, June 28, 2006 Art Unit: 1623 Phone: 571-272-0653 Serial Number: 10 / 632875	Jan Delaval Location: Biotech-Chem Library Remsen 1a51 Phone: 571-272-2504 jan.delaval@uspto.gov

Search Notes

Access DB# 192668

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester=s full Name: Devesh Khare Examiner #: 77931 Date: 06/12/2006
Art Unit: 1623 Phone Number 272-0653 Serial Number: 10/632,875
Mail Box: Remsen 5C18 and Bldg/Room Location: 5C35 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be search Include the elected species or structures, key words, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: 2',3'-dideoxynucleoside analogs for the treatment or prevention of flaviviridae inections.

Inventors (please provide full names): Raymond F. Schinazi; Robert Striker; Junxing Shi

Earliest priority Filing Date: **08/01/2002**

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please carry out a search on the attached claims sheet; examiner's hints provided.

Thank you.

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher:	NA Sequence (#)	STN ✓
Searcher Phone #: 22504	AA Sequence (#)	Dialog
Searcher Location:	Structure (#) ✓	Questel/Orbit
Date Searcher Picked Up: 6/27/06	Bibliographic	Dr. Link
Date Completed: 6/28/06	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems
Clerical prep time: 25 + 60	Patent Family	WWW/Internet
Online Time:	Other	Other (specify)

PTO-1590 (1-2000)

31. A pharmaceutical composition for the treatment and/or prophylaxis of an HCV infection in a host, comprising an effective treatment amount of a 2',3'-dideoxynucleoside of the formula:



or a pharmaceutically acceptable salt or prodrug thereof, wherein

(i) X is O, S, S=O, SO_2, NR^1, $N^+R^1R^2$, CH_2, CHF or CR^3R^4;

R^1 and R^2 are independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-8} cycloalkyl;

R^3 and R^4 are independently hydrogen, halogen (F, Cl, Br, or I), OH or OR^5;

R^5 is hydrogen or a hydroxyl protecting group such as alkyl, acyl or silyl;

(ii) Y is NH_2, NHR^6, NR^6R^7, OH or OR^8

each R^6, R^7 and R^7 is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, cyclopropyl, or C_{2-6} acyl;

(iii) Z is chosen from hydrogen, halogen (F, Cl, Br, or I), C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, CN, CF_3, N_3, NO_2, aryl, heteroaryl and COR^9;

R^9 is chosen from H, OH, SH, C_{1-6} alkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy and C_{1-6} thioalkyl; and

(iv) R is hydrogen, phosphate; acyl; $-C(O)R^{10}$, alkyl; sulfonate ester; sulfonyl; a lipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group, which, when administered *in vivo*, is capable of providing a compound wherein R is H or phosphate;

R^{10} is a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, monophosphate, diphosphate, triphosphate, or $-P(O)(OR^{11})_2$;

each R^{11} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or a hydroxyl-protecting group;

together with pharmaceutically acceptable carrier.

Examiner's hints and search points:

Please search the following specific compounds:

It has been found that β-L- or β-D-2',3'-dideoxynucleosides show inhibitory activity against *Flaviviridae* viruses, and in particular, HCV polymerase. Therefore, a

---

In one preferred embodiment, the active compound is β-L-2',3'-dideoxy-5-fluorocytidine (also referred to as β-L-ddFC), of the structure:









STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact***:

Mary Hale, Information Branch Supervisor
22507, Remsen 1d86

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

  Types of relevant prior art found:
  - ☐ Foreign Patent(s)
  - ☐ Non-Patent Literature
    (journal articles, conference proceedings, new product announcements etc.)
- *Relevant prior art **not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 09:13:56 ON 27 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 JUN 2006  HIGHEST RN 889573-50-6
DICTIONARY FILE UPDATES:  26 JUN 2006  HIGHEST RN 889573-50-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d sta que l14
L12             STR
```




```
VAR G1=N/O
```

```
VAR G2=O/S/N/C
NODE ATTRIBUTES:
CONNECT IS E2  RC AT  12
CONNECT IS E2  RC AT  13
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   9   5
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L14        3169 SEA FILE=REGISTRY SSS FUL L12

100.0% PROCESSED  119539 ITERATIONS                          3169 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 09:03:28 ON 27 JUN 2006)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 09:03:33 ON 27 JUN 2006
L1             2 S US20040067877/PN OR (US2003-632875# OR US2002-453715# OR US20
               E SCHINAZI/AU
L2           511 S E7,E8,E10-E12,E14,E16,E17
               E STRIKER/AU
L3            14 S E24,E28,E29
               E SHI/AU
L4             1 S E3
               E SHI J/AU
L5           316 S E3,E21
               E SHI JUN/AU
L6           534 S E3
L7            41 S E74-E77
               E SHI NAME/AU
L8             6 S E4
               E JUNXING/AU
               E PHARMASSET/PA,CS
L9            72 S E3-E31
L10         1431 S L1-L9
               SAV TEMP L10 KHARE632/A
               SEL RN L1

     FILE 'REGISTRY' ENTERED AT 09:07:04 ON 27 JUN 2006
L11          166 S E1-E166
               SAV TEMP L11 KHARE632A/A
L12            STR
L13           50 S L12
L14         3169 S L12 FUL
               SAV TEMP L14 KHARE632B/A
L15           16 S L11 AND L14
L16            1 S L15 AND C9H12FN3O3
L17           15 S L15 NOT L16

     FILE 'HCAOLD' ENTERED AT 09:10:23 ON 27 JUN 2006
L18            0 S L16
L19            0 S L17
```

```
     FILE 'HCAPLUS' ENTERED AT 09:10:27 ON 27 JUN 2006
L20          58 S L16
L21          70 S L17
L22          20 S L10 AND L20,L21
L23          73 S L21,L22 AND (PY<=2002 OR PRY<=2002 OR AY<=2002)
L24          19 S L22 AND L23
                E HEPATITIS C/CT
L25       11421 S E5+OLD,NT
L26        9774 S E3-E27
                E E27+ALL
L27        9774 S E7+NT
L28         207 S E6
                E E6+ALL
L29       13435 S E6+NT
                E HEPATITIS C/CT
                E E3+ALL
L30        6193 S E2,E3
L31           3 S L23 AND L25-L30
L32           1 S L24 AND L25-L30
L33           3 S L31,L32

     FILE 'REGISTRY' ENTERED AT 09:13:56 ON 27 JUN 2006

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:14:08 ON 27 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Jun 2006  VOL 145 ISS 1
FILE LAST UPDATED: 26 Jun 2006  (20060626/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d l33 all hitstr tot

L33  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:120958  HCAPLUS
DN   140:157421
ED   Entered STN:  13 Feb 2004
TI   2',3'-dideoxynucleoside analogs for the treatment or prevention of
     flaviviridae infections
IN   Shi, Junxing; Schinazi, Raymond F.; Striker,
     Robert
PA   Pharmasset Ltd., Barbados; Emory University; Board of Trustees
```

of the Leland Stanford Junior University
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N
CC 1-5 (Pharmacology)
Section cross-reference(s): 33
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004013298	A2	20040212	WO 2003-US24288	20030801 <--
	WO 2004013298	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003263978	A1	20040223	AU 2003-263978	20030801 <--
	US 2004067877	A1	20040408	US 2003-632875	20030801 <--
PRAI	US 2002-453715P	P	20020801 <--		
	US 2002-453716P	P	20020801 <--		
	WO 2003-US24288	W	20030801		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004013298	ICM	C12N
	IPCI	C12N [ICM,7]
	IPCR	A61K0031-513 [I,A]; A61K0031-513 [I,C*]; A61K0031-553 [I,A]; A61K0031-553 [I,C*]; A61K0031-58 [I,A]; A61K0031-58 [I,C*]; A61K0031-7042 [I,C*]; A61K0031-7056 [I,A]; A61K0031-7068 [I,A]; A61K0031-7072 [I,A]; A61K0038-20 [I,A]; A61K0038-20 [I,C*]; A61K0038-21 [I,A]; A61K0038-21 [I,C*]; C07H0019-00 [I,C*]; C07H0019-06 [I,A]
	ECLA	A61K031/513; A61K031/513+M; A61K031/553; A61K031/553+M; A61K031/58; A61K031/58+M; A61K031/7056+M; A61K031/7068; A61K031/7068+M; A61K031/7072; A61K031/7072+M; A61K038/20K+M; A61K038/21+M; C07H019/06
AU 2003263978	IPCI	A61K0031-7068 [ICM,7]; A61K0031-7042 [ICM,7,C*]
	IPCR	A61K0031-513 [I,A]; A61K0031-513 [I,C*]; A61K0031-553 [I,A]; A61K0031-553 [I,C*]; A61K0031-58 [I,A]; A61K0031-58 [I,C*]; A61K0031-7042 [I,C*]; A61K0031-7056 [I,A]; A61K0031-7068 [I,A]; A61K0031-7072 [I,A]; A61K0038-20 [I,A]; A61K0038-20 [I,C*]; A61K0038-21 [I,A]; A61K0038-21 [I,C*]; C07H0019-00 [I,C*]; C07H0019-06 [I,A]
US 2004067877	IPCI	A61K0038-16 [ICM,7]; A61K0031-58 [ICS,7]; A61K0031-7072 [ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-513 [ICS,7]
	IPCR	A61K0031-513 [I,A]; A61K0031-513 [I,C*]; A61K0031-553 [I,A]; A61K0031-553 [I,C*]; A61K0031-58 [I,A]; A61K0031-58 [I,C*]; A61K0031-7042 [I,C*]; A61K0031-7068 [I,A]; A61K0031-7072 [I,A]; A61K0038-20 [I,A]; A61K0038-20 [I,C*]; A61K0038-21 [I,A]; A61K0038-21 [I,C*]; C07H0019-00 [I,C*]; C07H0019-06 [I,A]

NCL 514/008.000
ECLA A61K031/513; A61K031/513+M; A61K031/553; A61K031/553+M; A61K031/58; A61K031/58+M; A61K031/7068; A61K031/7068+M; A61K031/7072; A61K031/7072+M; A61K038/20K+M; A61K038/21+M; C07H019/06

OS MARPAT 140:157421

AB A method for the treatment or prevention of flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a 2',3'-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient. Preparation of compds. of the invention is included.

ST dideoxynucleoside deriv prepn antiviral flaviviridae; hepatitis C virus antiviral dideoxynucleoside deriv

IT Deoxyribonucleosides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2',3'-dideoxyribonucleosides; dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT Gene, microbial
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NS5B; dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT Antiviral agents
Drug delivery systems
Flaviviridae
Hepatitis B virus
Hepatitis C virus
Human
Human immunodeficiency virus
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT Interferons
Interleukin 10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections, and use with other agents)

IT Infection
(viral; dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α, oral; dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections, and use with other agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ1b; dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections, and use with other agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ω; dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections, and use with other agents)

IT 7439-96-5, Manganese, biological studies 9026-28-2, RNA-dependent RNA polymerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dideoxynucleoside analog preparation for treatment or prevention of

flaviviridae infections)

IT **121154-51-6P 147058-39-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT **107036-57-7 121154-51-6D**, derivs. **147058-39-7D**
, derivs. **160963-15-5 160963-16-6 161170-31-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT 108-24-7, Acetic anhydride 2022-85-7, 5-Fluorocytosine 6893-26-1, D-Glutamic acid 34837-55-3, Benzeneselenenyl bromide 58479-61-1, tert-Butyldiphenylsilyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT 52813-63-5P 53558-93-3P 128075-94-5P **128112-71-0P**
153547-97-8P 153547-98-9P 169527-97-3P
189818-62-0P 189818-64-2P 189818-65-3P **189818-67-5P**
221156-18-9P 656798-97-9P 656798-98-0P **656798-99-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT **656799-00-7P 656799-01-8P 656799-03-0P**
656799-05-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

IT 56-92-8, Ceplene 768-94-5, Amantadine 36791-04-5, Ribavirin 62304-98-7, Zadaxin 118390-30-0, Infergen 119567-79-2, Viramidine 198153-51-4, Pegasys 198821-22-6, VX 497 206269-27-4, Levovirin 220581-49-7, Rebif 223603-41-6, ISIS 14803 254750-02-2, IDN-6556 402957-28-2, LY 570310 472960-22-8, Albuferon 632385-00-3, Heptazyme 656836-15-6, IP 501 656836-16-7, XTL 002 656836-17-8, HCV/MF 59 656836-18-9, Civacir 656836-19-0, JTK 003
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections, and use with other agents)

IT **121154-51-6P 147058-39-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

RN 121154-51-6 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 147058-39-7 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **107036-57-7 121154-51-6D**, derivs. **147058-39-7D**
, derivs. **160963-15-5 160963-16-6 161170-31-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)
RN 107036-57-7 HCAPLUS
CN Cytidine, 5-bromo-2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-51-6 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 147058-39-7 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 160963-15-5 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 160963-16-6 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-iodo-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161170-31-6 HCAPLUS

CN Triphosphoric acid, P-[(2R,5S)-[5-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **128112-71-0P 153547-97-8P 153547-98-9P 169527-97-3P 189818-67-5P 656798-99-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)

RN 128112-71-0 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153547-97-8 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153547-98-9 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 169527-97-3 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5R)-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189818-67-5 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 656798-99-1 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5R)-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **656799-00-7P 656799-01-8P 656799-03-0P**
656799-05-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(dideoxynucleoside analog preparation for treatment or prevention of flaviviridae infections)
RN 656799-00-7 HCAPLUS
CN Triphosphoric acid, P-[[(2R,5S)-5-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)

CM 1

CRN 161170-31-6
CMF C9 H15 F N3 O12 P3

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 656799-01-8 HCAPLUS
CN Triphosphoric acid, P-[[(2R,5S)-5-(4-amino-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)

CM 1

CRN 161170-30-5
CMF C9 H16 N3 O12 P3

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 656799-03-0 HCAPLUS
CN Triphosphoric acid, P-[[(2R,5S)-5-(5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)

CM 1

CRN 656799-02-9
CMF C9 H14 F N2 O13 P3

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 656799-05-2 HCAPLUS
CN Triphosphoric acid, P-[[(2R,5S)-5-(3,4-dihydro-2,4-dioxo-1(2H)-

pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)

CM 1

CRN 656799-04-1
CMF C9 H15 N2 O13 P3

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



L33 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:905731 HCAPLUS
DN 138:14152
ED Entered STN: 29 Nov 2002
TI Preparation of enzymic ribonucleic acid peptide conjugates as antitumor and antiviral agents and compositions for cellular delivery
IN Beigelman, Leonid; Matulic-Adamic, Jasenka; Vargeese, Chandra; Karpeisky, Alexander; Blatt, Lawrence; Shaffer, Christopher
PA Ribozyme Pharmaceuticals, Inc, USA
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 33-7 (Carbohydrates)
Section cross-reference(s): 1, 7, 34, 63
FAN.CNT 233

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094185	A2	20021128	WO 2002-US15876	20020520 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 9851819	A1	19980611	AU 1998-51819	19980112 <--
AU 729657	B2	20010208		
AU 9939188	A1	19990916	AU 1999-39188	19990713 <--
AU 769175	B2	20040115	AU 2000-56616	20000911 <--
EP 1572067	A2	20050914	EP 2002-746413	20020517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2447161	AA	20021128	CA 2002-2447161	20020520 <--
JP 2005505504	T2	20050224	JP 2002-590906	20020520 <--
US 2004110296	A1	20040610	US 2003-427160	20030430 <--
US 2004192626	A1	20040930	US 2003-444853	20030523 <--
US 2005080031	A1	20050414	US 2003-724270	20031126 <--
US 2004249178	A1	20041209	US 2004-780447	20040213 <--
US 2005096284	A1	20050505	US 2004-783128	20040220 <--
US 2005014172	A1	20050120	US 2004-798090	20040311 <--
US 2005048529	A1	20050303	US 2004-800487	20040315 <--
US 2005191638	A1	20050901	US 2004-824036	20040414 <--
US 2005032733	A1	20050210	US 2004-826966	20040416 <--
US 2005054598	A1	20050310	US 2004-830569	20040423 <--
US 2005148530	A1	20050707	US 2004-831620	20040423 <--
US 2005233996	A1	20051020	US 2004-832522	20040426 <--
US 2005137153	A1	20050623	US 2004-840731	20040506 <--
US 2005171039	A1	20050804	US 2004-844076	20040511 <--
US 2005159376	A1	20050721	US 2004-844072	20040512 <--
US 2005137155	A1	20050623	US 2004-861060	20040603 <--
US 2005143333	A1	20050630	US 2004-863973	20040609 <--
US 2005171040	A1	20050804	US 2004-864044	20040609 <--
US 2005119211	A1	20050602	US 2004-869638	20040616 <--
US 2005119212	A1	20050602	US 2004-871222	20040618 <--
US 2005209179	A1	20050922	US 2004-877889	20040625 <--
US 2005124566	A1	20050609	US 2004-879867	20040628 <--
US 2005130181	A1	20050616	US 2004-881118	20040630 <--
US 2005124567	A1	20050609	US 2004-883218	20040701 <--
US 2005124568	A1	20050609	US 2004-888226	20040709 <--
US 2005124569	A1	20050609	US 2004-892922	20040716 <--
US 2005164224	A1	20050728	US 2004-893010	20040716 <--
US 2005070497	A1	20050331	US 2004-894475	20040719 <--
US 2005176663	A1	20050811	US 2004-897902	20040723 <--
US 2005196765	A1	20050908	US 2004-898660	20040723 <--
US 2005277608	A1	20051215	US 2004-898311	20040723 <--
US 2005182006	A1	20050818	US 2004-903128	20040730 <--
US 2005159378	A1	20050721	US 2004-915896	20040811 <--
US 2005159379	A1	20050721	US 2004-916030	20040811 <--
US 2005158735	A1	20050721	US 2004-916095	20040811 <--
US 2005153914	A1	20050714	US 2004-918969	20040816 <--
US 2005164966	A1	20050728	US 2004-918896	20040816 <--
US 2005203040	A1	20050915	US 2004-918987	20040816 <--
US 2005176664	A1	20050811	US 2004-919866	20040817 <--
US 2005176665	A1	20050811	US 2004-919964	20040817 <--
US 2005233997	A1	20051020	US 2004-919584	20040817 <--
US 2005136436	A1	20050623	US 2004-923640	20040819 <--
US 2005153915	A1	20050714	US 2004-922544	20040819 <--
US 2005159380	A1	20050721	US 2004-922626	20040819 <--
US 2005159382	A1	20050721	US 2004-923580	20040819 <--
US 2005164967	A1	20050728	US 2004-922034	20040819 <--
US 2005079610	A1	20050414	US 2004-923115	20040820 <--
US 2005153916	A1	20050714	US 2004-923330	20040820 <--
US 2005159381	A1	20050721	US 2004-923522	20040820 <--
US 2005164968	A1	20050728	US 2004-923329	20040820 <--

	US 2005170371	A1	20050804	US 2004-922340	20040820 <--
	US 2005176666	A1	20050811	US 2004-923182	20040820 <--
	US 2005176024	A1	20050811	US 2004-923354	20040820 <--
	US 2005176025	A1	20050811	US 2004-923516	20040820 <--
	US 2005182007	A1	20050818	US 2004-922675	20040820 <--
	US 2005182008	A1	20050818	US 2004-923142	20040820 <--
	US 2005182009	A1	20050818	US 2004-923201	20040820 <--
	US 2005187174	A1	20050825	US 2004-923181	20040820 <--
	US 2005191618	A1	20050901	US 2004-923473	20040820 <--
	US 2005196767	A1	20050908	US 2004-923380	20040820 <--
	US 2005227935	A1	20051013	US 2004-923470	20040820 <--
	US 2005227936	A1	20051013	US 2004-923475	20040820 <--
	US 2005233344	A1	20051020	US 2004-923270	20040820 <--
	US 2005239731	A1	20051027	US 2004-923379	20040820 <--
	US 2005256068	A1	20051117	US 2004-923451	20040820 <--
	US 2005267058	A1	20051201	US 2004-922761	20040820 <--
	US 2005288242	A1	20051229	US 2004-923476	20040820 <--
	US 2005209180	A1	20050922	US 2004-942560	20040915 <--
	US 2005233998	A1	20051020	US 2004-944611	20040916 <--
	US 2005222066	A1	20051006	US 2004-962898	20041012 <--
	US 2005261219	A1	20051124	US 2004-1347	20041201 <--
	US 2005196781	A1	20050908	US 2004-14373	20041215 <--
	US 2006019913	A1	20060126	US 2005-31668	20050106 <--
	US 2006025361	A1	20060202	US 2005-35813	20050114 <--
	US 2005287128	A1	20051229	US 2005-54047	20050209 <--
	US 2005260620	A1	20051124	US 2005-58582	20050215 <--
	US 2005277133	A1	20051215	US 2005-63415	20050222 <--
	US 2005282188	A1	20051222	US 2005-98303	20050404 <--
	US 2006019917	A1	20060126	US 2005-140328	20050527 <--
PRAI	US 2001-292217P	P	20010518 <--		
	US 2001-306883P	P	20010720 <--		
	US 2001-311865P	P	20010813 <--		
	US 2002-362016P	P	20020306 <--		
	AU 1995-26422	A3	19950518 <--		
	US 1996-623891	A	19960325 <--		
	AU 1996-76662	A3	19961025 <--		
	US 2000-181797P	P	20000211 <--		
	US 2001-780533	B2	20010209 <--		
	WO 2001-US4273	A2	20010209 <--		
	US 2001-827395	B2	20010405 <--		
	US 2001-294140P	P	20010529 <--		
	US 2001-296249P	P	20010606 <--		
	US 2001-916466	B1	20010725 <--		
	US 2001-930423	B2	20010815 <--		
	US 2001-318471P	P	20010910 <--		
	US 2001-334461P	P	20011130 <--		
	US 2002-358580P	P	20020220 <--		
	US 2002-363124P	P	20020311 <--		
	WO 2002-US9187	A2	20020326 <--		
	WO 2002-US10512	A2	20020403 <--		
	US 2002-374722P	P	20020422 <--		
	US 2002-151116	A2	20020517 <--		
	WO 2002-US15876	W	20020520 <--		
	US 2002-157580	A2	20020529 <--		
	WO 2002-US16840	A2	20020529 <--		
	WO 2002-US17674	A2	20020529 <--		
	US 2002-163552	A2	20020606 <--		
	US 2002-386782P	P	20020606 <--		
	US 2002-393796P	P	20020703 <--		
	US 2002-393924P	P	20020703 <--		

US 2002-396600P	P	20020717	<--
US 2002-396905P	P	20020718	<--
US 2002-201394	A2	20020722	<--
US 2002-398036P	P	20020723	<--
US 2002-205309	A2	20020725	<--
US 2002-206705	A2	20020726	<--
US 2002-399348P	P	20020729	<--
US 2002-401093P	P	20020805	<--
US 2002-401104P	P	20020805	<--
US 2002-404039P	P	20020815	<--
US 2002-225023	A2	20020821	<--
US 2002-406784P	P	20020829	<--
US 2002-408378P	P	20020905	<--
US 2002-409293P	P	20020909	<--
US 2002-409493P	P	20020909	<--
US 2002-238700	A2	20020910	<--
US 2002-409785P	P	20020911	<--
US 2002-411275P	P	20020917	<--
US 2002-411707P	P	20020918	<--
US 2002-251117	A2	20020919	<--
US 2002-412304P	P	20020920	<--
US 2002-413714P	P	20020926	<--
US 2002-418655P	P	20021015	<--
US 2002-277494	B2	20021021	<--
US 2002-287949	A2	20021104	<--
US 2002-425559P	P	20021112	<--
US 2002-427467P	P	20021119	<--
US 2002-306747	A2	20021127	<--
US 2002-429359P	P	20021128	<--
US 2002-431105P	P	20021205	<--
US 2003-439922P	P	20030114	
US 2003-440129P	P	20030115	
WO 2003-US2510	A2	20030128	
WO 2003-US3473	A2	20030205	
WO 2003-US3662	A2	20030206	
WO 2003-US4034	A2	20030211	
WO 2003-US4088	A2	20030211	
WO 2003-US4123	A2	20030211	
WO 2003-US4347	A2	20030211	
WO 2003-US4566	A2	20030211	
WO 2003-US7273	A2	20030211	
WO 2003-US4250	A2	20030213	
WO 2003-US4317	A2	20030213	
WO 2003-US4397	A2	20030213	
WO 2003-US4402	A2	20030213	
WO 2003-US4448	A2	20030213	
WO 2003-US4710	A2	20030218	
WO 2003-US4738	A2	20030218	
WO 2003-US4907	A2	20030218	
WO 2003-US4908	A2	20030218	
WO 2003-US4909	A2	20030218	
WO 2003-US4741	A2	20030220	
WO 2003-US4951	A2	20030220	
WO 2003-US5022	A2	20030220	
WO 2003-US5028	A2	20030220	
WO 2003-US5043	A2	20030220	
WO 2003-US5044	A2	20030220	
WO 2003-US5045	A2	20030220	
WO 2003-US5162	A2	20030220	
WO 2003-US5190	A	20030220	

WO 2003-US5234	A2	20030220
WO 2003-US5326	A2	20030220
WO 2003-US5346	A2	20030220
US 2003-417012	A1	20030416
US 2003-420194	A2	20030422
WO 2003-US12626	A2	20030422
US 2003-422704	A2	20030424
US 2003-424339	A2	20030425
US 2003-427160	A2	20030430
US 2003-430882	A2	20030506
US 2003-444853	A2	20030523
US 2003-607933	A2	20030627
US 2003-486729P	P	20030711
US 2003-652791	A2	20030829
US 2003-664767	B2	20030916
US 2003-665255	A2	20030916
US 2003-667271	A2	20030916
US 2003-664668	A2	20030918
US 2003-665951	A2	20030918
US 2003-670011	A2	20030923
US 2003-683990	A2	20031010
US 2003-512701P	P	20031020
US 2003-693059	A2	20031023
US 2003-698311	A2	20031031
US 2003-712633	A2	20031113
US 2003-720448	A2	20031124
US 2003-724270	A2	20031126
US 2003-726236	A2	20031202
US 2003-727780	A2	20031203
US 2003-738128	A2	20031218
US 2004-758155	A2	20040112
US 2004-757803	A2	20040114
US 2004-764957	A2	20040126
US 2004-543480P	P	20040210
US 2004-780447	A2	20040213
US 2004-783128	A2	20040220
US 2004-798090	A2	20040311
US 2004-800487	A2	20040315
US 2004-824036	A2	20040414
US 2004-825485	A2	20040415
US 2004-826966	A2	20040416
WO 2004-US11848	A2	20040416
US 2004-830569	A2	20040423
US 2004-831620	A2	20040423
WO 2004-US12517	A2	20040423
US 2004-832522	A2	20040426
WO 2004-US13456	A2	20040430
US 2004-570086P	P	20040511
US 2004-844076	A2	20040511
US 2004-844072	A2	20040512
WO 2004-US16390	A2	20040524
US 2004-863973	A2	20040609
US 2004-894475	A2	20040719
US 2004-922675	A2	20040820
US 2004-923475	A2	20040820
US 2004-923536	A2	20040820
US 2004-944611	A2	20040916
US 2005-31668	A1	20050106
US 2005-39680	A2	20050118
WO 2005-US4270	A2	20050209

US 2005-98303 A2 20050404

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002094185	ICM	A61K
	IPCI	A61K [ICM,7]
	IPCR	A61K [I,S]; A61K0006-00 [I,A]; A61K0006-00 [I,C*]; A61K0031-519 [I,A]; A61K0031-519 [I,C*]; A61K0031-52 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-706 [I,A]; A61K0031-7088 [I,A]; A61K0031-7088 [I,C*]; A61K0031-712 [I,A]; A61K0031-712 [I,C*]; A61P0031-00 [I,C*]; A61P0031-12 [I,A]; A61P0031-14 [I,A]; A61P0031-16 [I,A]; A61P0031-18 [I,A]; A61P0031-20 [I,A]; A61P0035-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-02 [I,A]; A61P0043-00 [I,A]; A61P0043-00 [I,C*]; C07D0475-00 [I,A]; C07D0475-00 [I,C*]; C07D0475-04 [I,A]; C07H0019-00 [I,C*]; C07H0019-16 [I,A]; C07H0019-167 [I,A]; C07H0019-207 [I,A]; C07H0019-22 [I,A]; C07H0021-00 [I,A]; C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12P0017-18 [I,A]; C12P0017-18 [I,C*]; C12Q0001-68 [N,A]; C12Q0001-68 [N,C*]; G01N0033-53 [I,A]; G01N0033-53 [I,C*]
	ECLA	A61K047/48H4F4
AU 9851819	IPCI	C07H0021-02 [ICM,6]; C07H0021-04 [ICS,6]; C07H0021-00 [ICS,6,C*]; C12N0015-11 [ICS,6]; C12N0015-10 [ICS,6]; C12N0005-10 [ICS,6]; C12N0015-63 [ICS,6]; A61K0038-43 [ICS,6]; C12Q0001-68 [ICS,6]
	IPCR	A61K0038-43 [I,A]; A61K0038-43 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C07H0021-04 [I,A]; C12N0005-10 [I,A]; C12N0005-10 [I,C*]; C12N0015-10 [I,A]; C12N0015-10 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-63 [I,A]; C12N0015-63 [I,C*]; C12Q0001-68 [I,A]; C12Q0001-68 [I,C*]
AU 9939188	IPCI	C12N0015-11 [ICM,6]; C12N0009-00 [ICS,6]; C12N0005-10 [ICS,6]; A61K0048-00 [ICS,6]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C12N0005-10 [I,A]; C12N0005-10 [I,C*]; C12N0009-00 [I,A]; C12N0009-00 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]
AU 769175	IPCI	C12N0015-11 [ICM,7]; A61K0048-00 [ICS,7]; C12N0005-10 [ICS,7]; C12N0009-00 [ICS,7]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C12N0005-10 [I,A]; C12N0005-10 [I,C*]; C12N0009-00 [I,A]; C12N0009-00 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]
EP 1572067	IPCI	A61K0006-00 [ICM,7]
	IPCR	A61K [I,S]; A61K0006-00 [I,A]; A61K0006-00 [I,C*]; A61K0031-519 [I,A]; A61K0031-519 [I,C*]; A61K0031-52 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-706 [I,A]; A61K0031-7088 [I,A]; A61K0031-7088 [I,C*]; A61K0031-712 [I,A]; A61K0031-712 [I,C*]; A61P0031-00 [I,C*]; A61P0031-12 [I,A]; A61P0031-14 [I,A]; A61P0031-16 [I,A]; A61P0031-18 [I,A]; A61P0031-20 [I,A]; A61P0035-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-02 [I,A]; A61P0043-00 [I,A]; A61P0043-00 [I,C*]; C07D0475-00 [I,A]; C07D0475-00 [I,C*]; C07D0475-04 [I,A]; C07H0019-00 [I,C*]; C07H0019-16 [I,A]; C07H0019-167 [I,A]; C07H0019-207 [I,A]; C07H0019-22 [I,A];

C07H0021-00 [I,A]; C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12P0017-18 [I,A]; C12P0017-18 [I,C*]; C12Q0001-68 [N,A]; C12Q0001-68 [N,C*]; G01N0033-53 [I,A]; G01N0033-53 [I,C*]

ECLA A61K047/48H4F4

CA 2447161 IPCI C07D0475-00 [ICM,7]; C07H0021-00 [ICS,7]; A61P0035-00 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-00 [ICS,7,C*]; C07H0019-16 [ICS,7]; C07H0019-167 [ICS,7]; C07H0019-22 [ICS,7]; C07H0019-00 [ICS,7,C*]; A61K0031-519 [ICS,7]; A61K0031-52 [ICS,7]; A61K0031-7048 [ICS,7]; A61K0031-7052 [ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-7088 [ICS,7]

IPCR A61K [I,S]; A61K0006-00 [I,A]; A61K0006-00 [I,C*]; A61K0031-519 [I,A]; A61K0031-519 [I,C*]; A61K0031-52 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-706 [I,A]; A61K0031-7088 [I,A]; A61K0031-7088 [I,C*]; A61K0031-712 [I,A]; A61K0031-712 [I,C*]; A61P0031-00 [I,C*]; A61P0031-12 [I,A]; A61P0031-14 [I,A]; A61P0031-16 [I,A]; A61P0031-18 [I,A]; A61P0031-20 [I,A]; A61P0035-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-02 [I,A]; A61P0043-00 [I,A]; A61P0043-00 [I,C*]; C07D0475-00 [I,A]; C07D0475-00 [I,C*]; C07D0475-04 [I,A]; C07H0019-00 [I,C*]; C07H0019-16 [I,A]; C07H0019-167 [I,A]; C07H0019-207 [I,A]; C07H0019-22 [I,A]; C07H0021-00 [I,A]; C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12P0017-18 [I,A]; C12P0017-18 [I,C*]; C12Q0001-68 [N,A]; C12Q0001-68 [N,C*]; G01N0033-53 [I,A]; G01N0033-53 [I,C*]

ECLA A61K047/48H4F4

JP 2005505504 IPCI C07D0475-04 [ICM,7]; C07D0475-00 [ICM,7,C*]; A61K0031-519 [ICS,7]; A61K0031-706 [ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-712 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-14 [ICS,7]; A61P0031-16 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-20 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0035-00 [ICS,7]; A61P0035-02 [ICS,7]; A61P0043-00 [ICS,7]; C07H0019-207 [ICS,7]; C07H0019-00 [ICS,7,C*]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12P0017-18 [ICS,7]; G01N0033-53 [ICS,7]; C12Q0001-68 [ICS,7]

IPCR A61K [I,S]; A61K0006-00 [I,A]; A61K0006-00 [I,C*]; A61K0031-519 [I,A]; A61K0031-519 [I,C*]; A61K0031-52 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-706 [I,A]; A61K0031-7088 [I,A]; A61K0031-7088 [I,C*]; A61K0031-712 [I,A]; A61K0031-712 [I,C*]; A61P0031-00 [I,C*]; A61P0031-12 [I,A]; A61P0031-14 [I,A]; A61P0031-16 [I,A]; A61P0031-18 [I,A]; A61P0031-20 [I,A]; A61P0035-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-02 [I,A]; A61P0043-00 [I,A]; A61P0043-00 [I,C*]; C07D0475-00 [I,A]; C07D0475-00 [I,C*]; C07D0475-04 [I,A]; C07H0019-00 [I,C*]; C07H0019-16 [I,A]; C07H0019-167 [I,A]; C07H0019-207 [I,A]; C07H0019-22 [I,A]; C07H0021-00 [I,A]; C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12P0017-18 [I,A]; C12P0017-18 [I,C*]; C12Q0001-68 [N,A]; C12Q0001-68 [N,C*]; G01N0033-53 [I,A]; G01N0033-53 [I,C*]

FTERM 4B063/QA01; 4B063/QQ01; 4B063/QQ41; 4B063/QR41; 4B063/QR42; 4B063/QS36; 4B063/QX02; 4B063/QX07; 4B064/AE57; 4B064/CB06; 4B064/CC03; 4B064/CD12;

		4B064/DA01; 4C057/AA17; 4C057/AA18; 4C057/BB02; 4C057/BB05; 4C057/CC03; 4C057/DD01; 4C057/DD03; 4C057/LL34; 4C057/LL41; 4C057/MM04; 4C057/MM05; 4C057/MM09; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/CB09; 4C086/EA16; 4C086/EA18; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZB21; 4C086/ZB26; 4C086/ZB27; 4C086/ZB33; 4C086/ZC41; 4C086/ZC55
US 2004110296	IPCI	C12N0015-88 [ICM,7]; C12N0015-87 [ICM,7,C*]; C07J0001-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]
	NCL	435/458.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B3; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M
US 2004192626	IPCI	A61K0048-00 [ICM]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4F4; C12N015/11B1A; C12N015/11B3; C12N015/11D; C12N015/11H
US 2005080031	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K045/06; A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B2; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2004249178	IPCI	C07J0001-00 [ICM,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]
	NCL	552/506.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B3; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M
US 2005096284	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005014172	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005048529	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00

		[ICS,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005191638	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005032733	IPCI	A61K0048-00 [ICM]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005054598	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005148530	IPCI	C07H0021-02 [ICM,7]; C07H0021-00 [ICM,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]
	NCL	514/044.000
US 2005233996	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005137153	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005171039	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]
	NCL	514/044.000
US 2005159376	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]

	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005137155	IPCI	A61K0048-00 [ICM]; C07H0021-02 [ICS]; C07H0021-00 [ICS,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]; H01L0021-02 [I,C*]; H01L0021-331 [I,A]; H01L0029-02 [I,C*]; H01L0029-08 [I,A]; H01L0029-161 [N,A]; H01L0029-40 [I,C*]; H01L0029-45 [I,A]; H01L0029-66 [I,C*]; H01L0029-737 [I,A]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87; H01L021/331P2; H01L029/08B7; H01L029/45B; H01L029/737B
US 2005143333	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005171040	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005119211	IPCI	C07H0021-02 [ICM,7]; C07H0021-00 [ICM,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005119212	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B;

		C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005209179	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]
	NCL	514/044.000
US 2005124566	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0015-85 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005130181	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005124567	IPCI	A61K0048-00 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005124568	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005124569	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K045/06; A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B2; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005164224	IPCI	C12Q0001-68 [ICM,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48

		[I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005070497	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005176663	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005196765	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12Q0001-68 [I,A]; C12Q0001-68 [I,C*]
	NCL	435/006.000
US 2005277608	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005182006	IPCI	A61K0048-00 [ICM,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005159378	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005159379	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]

	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005158735	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005153914	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005164966	IPCI	A61K0048-00 [ICM,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005203040	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005176664	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005176665	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12Q0001-68 [I,A]; C12Q0001-68 [I,C*]
	NCL	514/044.000
US 2005233997	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00

		[ICS,7,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005136436	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005153915	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0015-85 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005159380	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005159382	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005164967	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005079610	IPCI	C07H0021-02 [ICM,7]; C07H0021-00 [ICM,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11

		[I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/375.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005153916	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005159381	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005164968	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005170371	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005176666	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005176024	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02

		[I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K045/06; A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B2; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005176025	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005182007	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005182008	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0031-7088 [I,A]; A61K0031-7088 [I,C*]; A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K031/7088; A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005182009	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005187174	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	514/044.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005191618	IPCI	A61K0048-00 [ICM,7]; C12Q0001-70 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]

	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12Q0001-70 [I,A]; C12Q0001-70 [I,C*]
	NCL	435/005.000
US 2005196767	IPCI	C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; A61K0048-00 [ICS,7]
	IPCR	A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]; C12N0015-87 [I,A]; C12N0015-87 [I,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005227935	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005227936	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005233344	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	435/006.000
	ECLA	A61K047/48H4; A61K047/48H4F4; C07H021/02; C12N015/11B; C12N015/11B1A; C12N015/11B5; C12N015/11B7; C12N015/11D; C12N015/11H; C12N015/11M; C12N015/87
US 2005239731	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005256068	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005267058	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005288242	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005209180	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]
	NCL	514/044.000
US 2005233998	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	514/044.000
US 2005222066	IPCI	A61K0048-00 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]
	NCL	514/044.000
US 2005261219	IPCI	A61K0048-00 [ICM,7]; C12N0015-85 [ICS,7]; C12Q0001-68 [ICS,7]
	NCL	514/044.000
US 2005196781	IPCI	A61K0048-00 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	IPCR	A61K0048-00 [I,A]; A61K0048-00 [I,C*]; C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C12Q0001-68 [I,A]; C12Q0001-68 [I,C*]
	NCL	435/006.000

US 2006019913	IPCI	A61K0048-00 [I,A]; C07H0021-02 [I,A]; C07H0021-00 [I,C*]
	NCL	514/044.000
US 2006025361	IPCI	A61K0048-00 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]
	NCL	514/044.000
US 2005287128	IPCI	A61K0048-00 [ICM,7]; C12N0005-08 [ICS,7]; C12N0015-85 [ICS,7]
	NCL	424/093.210
US 2005260620	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; A61K0048-00 [ICS,7]
	NCL	435/006.000
US 2005277133	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
	NCL	435/006.000
US 2005282188	IPCI	C12Q0001-68 [ICM,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]; A61K0048-00 [ICS,7]
	NCL	435/006.000
US 2006019917	IPCI	A61K0048-00 [I,A]; C07H0021-04 [I,A]; C07H0021-02 [I,A]; C07H0021-00 [I,C*]
	NCL	514/044.000

GI



I

AB This invention features peptide nucleotide conjugates I wherein each R1-R8 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, or a protecting group, each "n" is independently an integer from 0 to about 200, R9 is a straight or branched chain alkyl, substituted alkyl, aryl, or substituted aryl, and R2 is a phosphorus containing group, nucleoside, nucleotide, small mol., nucleic acid, or a solid support comprising a linker., degradable linkers, compns., methods of synthesis, and applications thereof, including folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HAS) derived conjugates of biol. active compds., including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers. Thus, 1-O-(4-monomethoxytrityl)-N-(12'-hydroxydodecanoyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-3-D-galactopyranose)-D-threoninol 3-O-(2-cyanoethyl,N,N-diisopropylphosphorami-dite) was prepared and incorporated into RNA. A method of treating a cancer patient, comprising contacting cells of patient wherein said cancer is breast cancer, lung cancer, colorectal cancer, brain cancer, esophageal cancer, stomach cancer, bladder cancer, pancreatic cancer, cervical cancer, head and neck cancer, ovarian cancer, melanoma, lymphoma, glioma, or multidrug resistant cancers and/or viral

infections including HIV, HBV, HCV, CMV, RSV, HSV, poliovirus, influenza, rhinovirus, west nile virus, Ebola virus, foot and mouth virus, and papilloma.

ST antitumor multidrug resistant nucleotide RNA enzyme prepn; hormone nucleoside nucleotide RNA enzyme antisense prepn antiviral glycophospholipid; antibody enzymic oligoribonucleotide peptide prepn antiviral hammerhead enzyme antisense; enzymic ribonucleic acid peptide prepn antiviral triplex oligoribonucleotide human

IT Quaternary structure
(DNA triplex; preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Uterus, neoplasm
(cervix; preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Nucleic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(enzymic-hammerhead, inozyme, DNAzyme, G-cleaver, zinzyme, amberzyme and allozyme; preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human serum; preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Antitumor agents
Antiviral agents
Brain
Brain, neoplasm
Cytomegalovirus
Ebola virus
Foot-and-mouth disease virus
Head and Neck
Head and Neck
Hepatitis B virus
Hepatitis C virus
Human
Human immunodeficiency virus
Human poliovirus
Influenza
Lung
Lung, neoplasm
Lymphoma
Mammary gland
Mammary gland, neoplasm
Melanoma
Multidrug resistance
Neoplasm
Neuroglia, neoplasm
Ovary, neoplasm
Pancreas
Pancreas, neoplasm
Papilloma
Papillomavirus
Rhinovirus
Rous sarcoma virus
Stomach
West Nile virus
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Enzymes, biological studies
Glycophospholipids

Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Glycopeptides
Nucleotides, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Double stranded RNA
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT Infection
(viral; preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT 316-46-1 5536-17-4 21679-14-1, Fludarabine 29984-33-6 30516-87-1, AZT 36791-04-5, Ribavirin 39809-25-1, Penciclovir 59277-89-3, Acyclovir 69123-98-4, Fialuridine 82410-32-0, Ganciclovir 104227-87-4, Famciclovir 114987-19-8, Cytallene **121154-51-6** 127759-89-1, Lobucavir 134678-17-4, Lamivudine 142217-69-4, BMS 200475 142340-99-6 143491-54-7, FTC 147058-39-7 163252-36-6, L-FMAU
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT 100-66-3, Anisole, reactions 150-13-0 524-38-9, N-Hydroxyphthalimide 616-30-8 1811-31-0 2127-03-9 2592-95-2, 1-Hydroxybenzotriazole 14470-28-1, p-Anisylchlorodiphenylmethane 30453-21-5D, enzymic nucleic acid derivs. 84793-07-7 88574-06-5 109581-83-1 133906-29-3 173209-23-9 252847-30-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT 10385-50-9P 99837-97-5P 141925-93-1P 449807-11-8P 449807-12-9P 449807-13-0P 449807-14-1P 449807-15-2P 449807-17-4P 449807-19-6P 449807-20-9P 449807-21-0P 449807-22-1P 449807-24-3P 449807-25-4P 449807-26-5P 475575-52-1P 475575-53-2P 475575-54-3P 475575-55-4P 475575-56-5DP, enzymic nucleic acid derivs. 475575-57-6P 475575-58-7P 475575-59-8P 475575-60-1P 475575-61-2P 475575-62-3P 475575-85-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT 477694-12-5 477694-13-6 477694-14-7 477694-15-8 477694-16-9 477694-17-0 477694-18-1 477694-19-2
RL: PRP (Properties)
(unclaimed nucleotide sequence; preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT 123251-89-8 143189-32-6 161007-71-2 188842-14-0 199792-56-8 213546-53-3 220337-28-0 395069-93-9 477586-11-1 477586-12-2 477586-13-3 477586-14-4
RL: PRP (Properties)
(unclaimed sequence; preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)

IT **121154-51-6**

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of enzymic RNA peptide conjugates as antitumor and antiviral agents and compns. for cellular delivery)
RN 121154-51-6 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L33 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:617821 HCAPLUS
DN 135:175348
ED Entered STN: 24 Aug 2001
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
IN Mueller, Richard A.; Bryant, Martin L.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K0031-445
ICS A61P0031-14
CC 1-5 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060366	A1	20010823	WO 2001-US4512	20010213 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001036938	A5	20010827	AU 2001-36938	20010213 <--
	EP 1261339	A1	20021204	EP 2001-909153	20010213 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003522791	T2	20030729	JP 2001-559463	20010213 <--
	US 2005119310	A1	20050602	US 2002-203769	20010213 <--
PRAI	US 2000-182362P	P	20000214 <--		
	WO 2001-US4512	W	20010213 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001060366	ICM	A61K0031-445
	ICS	A61P0031-14

	IPCI	A61K0031-445 [ICM,7]; A61P0031-14 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	ECLA	A61K031/445; A61K045/06
AU 2001036938	IPCI	A61K0031-445 [ICM,7]; A61P0031-14 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
EP 1261339	IPCI	A61K0031-445 [ICM,6]; A61P0031-14 [ICS,6]; A61P0031-00 [ICS,6,C*]
	IPCR	A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
JP 2003522791	IPCI	A61K0031-445 [ICM,7]; A61P0001-16 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0031-20 [ICS,7]; A61P0031-00 [ICS,7,C*]; C07D0211-46 [ICS,7]; C07D0211-00 [ICS,7,C*]
	IPCR	A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
US 2005119310	IPCI	A61K0031-445 [ICM,7]
	NCL	514/328.000

AB Provided are methods and compns. for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixts. thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixts. thereof, and immunomodulating/immuno stimulating agents.

ST hepatitis virus iminoglucitol deriv nucleoside nucleotide; immunomodulator antiviral hepatitis virus iminoglucitol deriv

IT **Hepatitis**
(B; treatment of hepatitis B and **C** virus infections with dideoxyiminoglucitols and antiviral nucleosides and nucleotides)

IT **Hepatitis**
(**C**; treatment of hepatitis B and **C** virus infections with dideoxyiminoglucitols and antiviral nucleosides and nucleotides)

IT Antiviral agents
Hepatitis B virus
Hepatitis C virus
Immunomodulators
Immunostimulants
(treatment of hepatitis B and C virus infections with dideoxyiminoglucitols and antiviral nucleosides and nucleotides)

IT 3056-17-5, Stavudine 5536-17-4, Ara-A 7481-89-2, Dideoxycytidine 25526-93-6 29984-33-6, Ara-AMP 30516-87-1, 3'-Azido-3'-deoxythymidine 36791-04-5, 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide 39809-25-1, Penciclovir 59277-89-3, Acyclovir 66341-18-2, Acyclovir triphosphate 69123-90-6, FIAC 69123-98-4, FIAU 69256-17-3, FMAU 69655-05-6, Dideoxyinosine 72458-45-8 72458-46-9 73243-67-1 77222-61-8 79206-10-3 79206-12-5 79206-14-7 79206-20-5 79206-22-7 79570-63-1 81117-35-3 81117-36-4 81117-38-6 82410-32-0, Ganciclovir 85326-06-3 87190-81-6 104227-87-4, Famciclovir 106941-25-7, PMEA 111687-37-7, D-Carbocyclic-2'-deoxyguanosine 115183-38-5 115249-95-1 **121154-51-6** 128985-11-5 131167-83-4 134678-17-4, 3TC 134680-32-3 137530-41-7 143491-54-7, FTC 143491-57-0 143616-58-4 147058-39-7 160632-03-1 160632-05-3 162398-48-3 162398-56-3 211987-28-9 211987-29-0 211987-30-3 211987-31-4 211987-32-5 211987-33-6 211987-34-7 211987-35-8 211987-36-9 211987-37-0 211987-38-1 211987-39-2 211987-40-5 211987-41-6 211987-42-7 211987-43-8 211987-44-9

211987-45-0 211987-46-1 211987-47-2 211987-48-3 211987-49-4
211987-50-7 211987-51-8 211987-52-9 211987-53-0 211987-54-1
211987-55-2 211987-56-3 211987-57-4 211987-58-5 211987-59-6
211987-60-9 211987-61-0 211987-62-1 223771-90-2 223772-09-6
238075-04-2 238075-05-3 238075-06-4 238075-07-5 238075-08-6
238075-09-7 238075-10-0 238075-11-1 238075-12-2 238075-13-3
238075-14-4 238075-15-5 238075-16-6 238075-17-7 238075-18-8
238075-19-9 238075-20-2 238075-21-3 238075-22-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of hepatitis B and C virus infections with dideoxyiminoglucitols and antiviral nucleosides and nucleotides)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Block, T; NATURE MEDICINE 1998, V4(5), P610 HCAPLUS
(2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 HCAPLUS
(3) Dwek, R; WO 9835685 A 1998 HCAPLUS
(4) Mueller, R; WO 9940916 A 1999 HCAPLUS
(5) Mueller, R; WO 0047198 A 2000 HCAPLUS
(6) Platt, F; CHEMTRACTS ORGANIC CHEMISTRY 1994, P106
(7) Searle & Co; WO 9519172 A 1995 HCAPLUS
(8) Zitzmann, N; WO 9929321 A 1999 HCAPLUS
(9) Zitzmann, N; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1999, V96(21), P11878 HCAPLUS

IT **121154-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of hepatitis B and C virus infections with dideoxyiminoglucitols and antiviral nucleosides and nucleotides)

RN 121154-51-6 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=> fil reg
FILE 'REGISTRY' ENTERED AT 09:14:24 ON 27 JUN 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JUN 2006 HIGHEST RN 889573-50-6
DICTIONARY FILE UPDATES: 26 JUN 2006 HIGHEST RN 889573-50-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> => d ide can l16

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **147058-39-7** REGISTRY
ED Entered STN: 20 Apr 1993
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-, (2S-cis)-
OTHER NAMES:
CN β-L-2',3'-Dideoxy-5-fluorocytidine
FS STEREOSEARCH
DR 174541-05-0
MF **C9 H12 F N3 O3**
SR CA
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PROUSDDR, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

58 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
58 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:488682

REFERENCE 2: 142:170033

REFERENCE 3: 141:400969

REFERENCE 4: 141:325184

REFERENCE 5: 141:225774

REFERENCE 6: 140:157421

REFERENCE 7: 138:14152

REFERENCE 8: 137:333119

REFERENCE 9: 136:144693

REFERENCE 10: 136:47974

=> d ide can l17 tot

L17 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **656799-05-2** REGISTRY
ED Entered STN: 02 Mar 2004
CN Triphosphoric acid, P-[[(2R,5S)-5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H15 N2 O13 P3 . x C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 656799-04-1
CMF C9 H15 N2 O13 P3

From applicants:

10/632875

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

L17 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **656799-03-0** REGISTRY
ED Entered STN: 02 Mar 2004
CN Triphosphoric acid, P-[[(2R,5S)-5-(5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H14 F N2 O13 P3 . x C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 656799-02-9
CMF C9 H14 F N2 O13 P3

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

L17 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **656799-01-8** REGISTRY
ED Entered STN: 02 Mar 2004
CN Triphosphoric acid, P-[[(2R,5S)-5-(4-amino-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H16 N3 O12 P3 . x C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 161170-30-5
CMF C9 H16 N3 O12 P3

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

L17 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **656799-00-7** REGISTRY
ED Entered STN: 02 Mar 2004
CN Triphosphoric acid, P-[[(2R,5S)-5-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H15 F N3 O12 P3 . x C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 161170-31-6
CMF C9 H15 F N3 O12 P3

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

L17 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **656798-99-1** REGISTRY
ED Entered STN: 02 Mar 2004
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5R)-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-5-fluoro-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H29 F N2 O4 Si
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

L17 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **189818-67-5** REGISTRY
ED Entered STN: 13 Jun 1997
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-5-fluoro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-5-fluoro-, (2S-cis)-
FS STEREOSEARCH
MF C25 H30 F N3 O3 Si
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 128:308706

REFERENCE 3: 128:75639

REFERENCE 4: 126:343801

L17 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **169527-97-3** REGISTRY
ED Entered STN: 02 Nov 1995
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5R)-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2S-cis)-
FS STEREOSEARCH
MF C25 H30 N2 O4 Si
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 123:286530

L17 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **161170-31-6** REGISTRY
ED Entered STN: 02 Mar 1995
CN Triphosphoric acid, P-[(2R,5S)-[5-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Triphosphoric acid, P-[[5-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester, (2R-cis)-
FS STEREOSEARCH
MF C9 H15 F N3 O12 P3
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 132:329401

REFERENCE 3: 129:103801

REFERENCE 4: 126:139863

REFERENCE 5: 126:69690

REFERENCE 6: 124:306640

REFERENCE 7: 124:215

REFERENCE 8: 122:154909

L17 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **160963-16-6** REGISTRY
ED Entered STN: 21 Feb 1995
CN 2(1H)-Pyrimidinone, 4-amino-5-iodo-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Pyrimidinone, 4-amino-5-iodo-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-, (2S-cis)-
FS STEREOSEARCH
MF C9 H12 I N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 122:123093

L17 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **160963-15-5** REGISTRY
ED Entered STN: 21 Feb 1995
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-, (2S-cis)-
FS STEREOSEARCH
MF C9 H12 Cl N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:325184

REFERENCE 2: 140:157421

REFERENCE 3: 136:47974

REFERENCE 4: 133:83920

REFERENCE 5: 122:123093

L17 ANSWER 11 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **153547-98-9** REGISTRY
ED Entered STN: 10 Mar 1994
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4(1H,3H)-Pyrimidinedione, 1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-, (2S-cis)-
OTHER NAMES:
CN β-L-2',3'-Dideoxyuridine
FS STEREOSEARCH
MF C9 H12 N2 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 135:167014

REFERENCE 3: 132:132349

REFERENCE 4: 126:343812

REFERENCE 5: 126:104343

REFERENCE 6: 125:115093

REFERENCE 7: 125:108579

REFERENCE 8: 123:286530

REFERENCE 9: 122:282253

REFERENCE 10: 122:123093

L17 ANSWER 12 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **153547-97-8** REGISTRY
ED Entered STN: 10 Mar 1994
CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-, (2S-cis)-
FS STEREOSEARCH
MF C9 H11 F N2 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 123:286530

REFERENCE 3: 120:182418

L17 ANSWER 13 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **128112-71-0** REGISTRY
ED Entered STN: 13 Jul 1990
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-5-[[[(1,1-

dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2S-cis)-
FS STEREOSEARCH
MF C25 H31 N3 O3 Si
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 113:41231

L17 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **121154-51-6** REGISTRY
ED Entered STN: 16 Jun 1989
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Pyrimidinone, 4-amino-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-, (2S-cis)-
OTHER NAMES:
CN β-L-2',3'-Dideoxycytidine
CN 36: PN: DE102004051804 PAGE: 22 claimed sequence
CN L-DdC
FS STEREOSEARCH
MF C9 H13 N3 O3
SR CA
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMINFORMRX, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

51 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
51 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:425654

REFERENCE 2: 143:194107

REFERENCE 3: 141:325184

REFERENCE 4: 140:157421

REFERENCE 5: 138:14152

REFERENCE 6: 137:29517

REFERENCE 7: 136:397775

REFERENCE 8: 136:355410

REFERENCE 9: 136:47974

REFERENCE 10: 135:205124

L17 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2006 ACS on STN
RN **107036-57-7** REGISTRY
ED Entered STN: 14 Mar 1987
CN Cytidine, 5-bromo-2',3'-dideoxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2',3'-Dideoxy-5-bromocytidine
CN 5-Bromo-2',3'-dideoxycytidine
FS STEREOSEARCH
MF C9 H12 Br N3 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157421

REFERENCE 2: 122:123093

REFERENCE 3: 113:17495

REFERENCE 4: 112:36348

REFERENCE 5: 112:18094

REFERENCE 6: 111:58275

REFERENCE 7: 108:269

REFERENCE 8: 106:156808

=>

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 08:37:29 ON 28 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 JUN 2006  HIGHEST RN 889765-67-7
DICTIONARY FILE UPDATES:  27 JUN 2006  HIGHEST RN 889765-67-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d sta que 15
L1              STR
```




```
VAR G1=N/O
```

VAR G2=O/S/N/C
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 12
CONNECT IS E2 RC AT 13
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 9 5
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L2 3169 SEA FILE=REGISTRY SSS FUL L1
L3 STR



VAR G1=N/16/23/O/27
VAR G2=O/S/43/SO2/N/48/45/C/50/52
VAR G3=AK/CB/19
VAR G4=C/28
VAR G5=X/AK/CN/CF3/30/NO2/CY/CHO/34
VAR G6=O/S/AK/41/42/37/39
VAR G7=AK/CB
VAR G8=X/OH/37/55/59
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 15
CONNECT IS M1 RC AT 60
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 5 9

NUMBER OF NODES IS 55

STEREO ATTRIBUTES: NONE
L5 1913 SEA FILE=REGISTRY SUB=L2 CSS FUL L3

100.0% PROCESSED 3103 ITERATIONS 1913 ANSWERS
SEARCH TIME: 00.00.01

=> d ide can l17

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **9026-28-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN Nucleotidyltransferase, ribonucleate, RNA-dependent (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3D Polymerase
CN E.C. 2.7.7.48
CN Gene PB2 polymerase
CN Hepatitis C virus polymerase
CN Hepatitis C virus polymerase NS5B
CN NS5B polymerase
CN NS5B RNA-dependent RNA polymerase
CN PB1 polymerase
CN PB1 proteins
CN PB2 polymerase
CN PB2 proteins
CN Phage f2 replicase
CN Polymerase L
CN Proteins, λ3, of reovirus
CN Proteins, PB 2
CN Proteins, PB1
CN Q-Beta replicase
CN Qβ-replicase
CN Replicase, phage f2
CN Replicase, Qβ-
CN Ribonucleic acid replicase
CN Ribonucleic acid-dependent ribonucleate nucleotidyltransferase
CN Ribonucleic acid-dependent ribonucleic acid polymerase
CN Ribonucleic replicase
CN Ribonucleic synthetase
CN RNA replicase
CN RNA synthetase
CN RNA transcriptase
CN RNA-dependent ribonucleate nucleotidyltransferase
CN RNA-dependent RNA polymerase
CN RNA-dependent RNA polymerase NS5B
CN RNA-dependent RNA replicase
CN RNA-directed RNA polymerase
CN Transcriptase
MF Unspecified
CI MAN
LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CIN, EMBASE, PROMT, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
            3603 REFERENCES IN FILE CA (1907 TO DATE)
              38 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            3617 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  145:4051

REFERENCE   2:  145:1919

REFERENCE   3:  145:1750

REFERENCE   4:  145:1575

REFERENCE   5:  144:487147

REFERENCE   6:  144:484776

REFERENCE   7:  144:484443

REFERENCE   8:  144:484408

REFERENCE   9:  144:483276

REFERENCE  10:  144:483256


=> d his

     (FILE 'HOME' ENTERED AT 07:50:33 ON 28 JUN 2006)
                SET COST OFF

     FILE 'REGISTRY' ENTERED AT 07:51:12 ON 28 JUN 2006
                ACT KHARE632B/A
               ---------
L1              STR
L2           3169 SEA FILE=REGISTRY SSS FUL L1
               ---------
L3              STR L1
L4             50 S L3 CSS SAM SUB=L2
L5           1913 S L3 CSS FUL SUB=L2
                SAV TEMP L5 KHARE632C/A

     FILE 'HCAPLUS' ENTERED AT 08:20:11 ON 28 JUN 2006
L6           4074 S L5
L7             48 S L6 AND HCV
L8             79 S L6 AND HEPATITIS C VIRUS
L9             95 S L6 AND HEPATITIS C
                E HEPATITIS C/CT
                E E3+ALL
L10          6197 S E2,E3
                E E5+ALL
                E HEPATITIS C/CT
L11            98 S E10-E27
                E E5+ALL
L12         11424 S E8+OLD,NT
                E E7+ALL
L13          9777 S E7+NT
                E HEPATITIS C/CT
L14            88 S L6 AND L10-L13
L15            95 S L7-L9,L14
L16            98 S HCV POLYMERASE
```

```
     FILE 'REGISTRY' ENTERED AT 08:26:13 ON 28 JUN 2006
L17             1 S 9026-28-2

     FILE 'HCAPLUS' ENTERED AT 08:26:26 ON 28 JUN 2006
L18          3617 S L17
L19            16 S L6 AND L16,L18
L20             7 S L6 AND RNA DEPENDENT RNA POLYMERASE
L21             0 S L6 AND NS5B POLYMERASE
L22           504 S L6 AND POLYMERASE
L23            18 S L22 AND L15
L24           101 S L15,L19,L23
L25            62 S L24 AND (PY<=2002 OR PRY<=2002 OR AY<=2002)
L26            53 S L5 (L) (THU OR PAC OR PKT OR DMA)/RL AND L25
L27            56 S L24 AND (PD<=20020801 OR PRD<=20020801 OR AD<=20020801)
L28            47 S L26 AND L27
L29             9 S L27 NOT L28
                  SEL AN 5 6 8
L30             3 S L29 AND E1-E6
L31            47 S L28 AND HEPATITIS
L32             2 S L24 AND (SCHINAZI ? OR STRIKER ? OR SHI J?)/AU
L33             3 S L24 AND PHARMASSET?/PA,CS
L34             4 S L32,L33
L35             3 S L34 NOT 140:157421/DN
L36            51 S L30,L31,L35 AND L6-L16,L18-L35
L37            50 S L36 NOT 140:157421/DN

     FILE 'REGISTRY' ENTERED AT 08:37:29 ON 28 JUN 2006

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:37:44 ON 28 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Jun 2006  VOL 145 ISS 1
FILE LAST UPDATED: 27 Jun 2006  (20060627/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d 137 bib abs hitstr retable tot

L37  ANSWER 1 OF 50  HCAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:238670  HCAPLUS
DN   142:303644
TI   Compositions comprising phosphatidylethanolamine-binding peptides linked
```

to anti-viral agents
IN Thorpe, Philip E.; Soares, M. Melina; He, Jin
PA USA
SO U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of U.S. Ser. No. 621,269.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005059578	A1	20050317	US 2003-642121	20030815 <--
	US 2004170620	A1	20040902	US 2003-621269	20030715 <--
PRAI	US 2002-396263P	P	20020715	<--	
	US 2003-621269	A2	20030715		

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases. The pharmaceutical compns. and treatment methods of the invention employ "therapeutically effective amts." of an anti-aminophospholipid or anti-anionic phospholipid antibody, optionally one that binds to substantially the same epitope as the monoclonal antibody 9D2 or 3G4, or an antigen binding fragment or immunoconjugate of such an antibody, or a substantially cell impermeant PE-binding peptide derivative, preferably a substantially cell impermeant duramycin derivative, or an anti-viral conjugate thereof.

IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compns. comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 2 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:177803 HCAPLUS
DN 142:254560
TI Antimetabolite antiviral dosing regimen for **hepatitis C virus** or flaviviridae therapy
IN Stuyver, Lieven J.
PA **Pharmasset, Inc., USA**
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005018330	A1	20050303	WO 2004-US26686	20040817
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-496202P	P	20030818		

AB An anti-**hepatitis C** agent which is an anti-metabolite to the host and cannot be administered on a daily or chronic basis as is usual in anti-viral therapy (referred to below as an "anti-**HCV** anti-metabolite"), can be administered using a traditional anti-cancer dosing regimen (for example via i.v. or parenteral injection), over a period of 1-7 days followed by cessation of therapy until rebound of the viral load is noted. This dosing regimen runs counter to conventional antiviral experience, wherein effective agents are usually administered over at least fourteen days of sustained therapy, and typically on an indefinite daily basis.

IT **7481-89-2**, Zalcitabine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimetabolite antiviral dosing regimen for **hepatitis C virus** or flaviviridae therapy)
RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **9026-28-2, RNA dependent RNA polymerase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, combination; antimetabolite antiviral dosing regimen for **hepatitis C virus** or flaviviridae therapy)
RN 9026-28-2 HCAPLUS
CN Nucleotidyltransferase, ribonucleate, RNA-dependent (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Frustaci	2002	122	1348	Chest	
Sato	2002	97	215	AM J Gastroeenterolo	

L37 ANSWER 3 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:98834 HCAPLUS
DN 142:196516
TI Anti-phosphatidylserine antibodies and antibody-antiviral agent conjugates for treating cancer and viral infection
IN Thorpe, Philip E.; Soares, M. Melina; He, Jin
PA Board of Regents, the University of Texas System, USA
SO U.S. Pat. Appl. Publ., 180 pp., Cont.-in-part of U.S. Ser. No. 621,269.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005025761	A1	20050203	US 2003-642100	20030815 <--
	US 2004170620	A1	20040902	US 2003-621269	20030715 <--
PRAI	US 2002-396263P	P	20020715 <--		
	US 2003-621269	A2	20030715		

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases. E.g. anti--phosphatidylserine antibody 3G4 and scFv 3A2 and 9D2 and their humanized derivs. were prepared for treatment of cancer and viral infection.
IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(anti-phosphatidylserine antibodies and antibody-antiviral agent conjugates for treating cancer and viral infection)
RN 3056-17-5 HCAPLUS

CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 4 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:905361 HCAPLUS
DN 141:388642
TI Methods for treating tumors and viral infections by using antibodies, immunoconjugates and duramycin-based compounds to inhibit anionic phospholipids and aminophospholipids
IN Thorpe, Philip E.; Soares, M. Melina; Ran, Sophia
PA USA
SO U.S. Pat. Appl. Publ., 181 pp., Cont.-in-part of U.S. Ser. No. 621,269.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004213779	A1	20041028	US 2003-642119	20030815 <--
	US 2004170620	A1	20040902	US 2003-621269	20030715 <--
PRAI	US 2002-396263P	P	20020715	<--	
	US 2003-621269	A2	20030715		

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treating tumors and viral infections by using antibodies,

immunoconjugates and duramycin-based compds. to inhibit anionic phospholipids and aminophospholipids)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 5 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:490275 HCAPLUS
DN 141:59691
TI Systemic delivery of antiviral agents
IN Ashton, Paul; Chen, Jianbing; Smith, Thomas J.
PA Control Delivery Systems, Inc., USA
SO U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 96,877.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004115268	A1	20040617	US 2003-713336	20031113 <--
	US 6375972	B1	20020423	US 2000-558207	20000426 <--
	US 2002102307	A1	20020801	US 2002-96877	20020314 <--
	US 2005186279	A1	20050825	US 2005-81142	20050315 <--
PRAI	US 2000-558207	A1	20000426 <--		
	US 2002-96877	A2	20020314 <--		
	US 2002-425943P	P	20021113 <--		

AB The systems and methods disclosed herein provide sustained delivery of a therapeutic agent for treating a patient, e.g., human, to obtain a desired local or systemic physiol. or pharmacol. effect. Method includes positioning the sustained released drug delivery system at an area wherein release of the agent is desired and allowing the agent to pass through the device to the desired area of treatment. In some embodiments, the method is for treating or reducing the risk of retroviral or lentiviral

infection. In certain embodiments, the method is for preventing or reducing the risk of mother-to-child transmission of HIV, wherein the therapeutic agent is an antiviral agent.

IT **3416-05-5**, 2',3'-Dideoxythymidine **7481-89-2**, Zalcitabine
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(systemic delivery of antiviral agents)

RN 3416-05-5 HCAPLUS
CN Thymidine, 3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 6 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:60253 HCAPLUS
DN 140:127195
TI Antibodies specifically bind to anionic phospholipids and/or aminophospholipids conjugated with duramycin peptide for treating viral infections and cancer
IN Thorpe, Philip E.; Soares, Melina M.; Huang, Xianming; He, Jin; Ran, Sophia
PA Board of Regents the University of Texas System, USA
SO PCT Int. Appl., 378 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006847	A2	20040122	WO 2003-US21925	20030715 <--
	WO 2004006847	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2491310	AA	20040122	CA 2003-2491310	20030715	<--
AU 2003247869	A1	20040202	AU 2003-247869	20030715	<--
US 2004175378	A1	20040909	US 2003-620850	20030715	<--
EP 1537146	A2	20050608	EP 2003-764600	20030715	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1668644	A	20050914	CN 2003-816751	20030715	<--
JP 2005537267	T2	20051208	JP 2004-521771	20030715	<--
PRAI US 2002-396263P	P	20020715	<--		
WO 2003-US21925	W	20030715			

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

IT **3056-17-5D**, Stavudine, conjugates **7481-89-2D**, Zalcitabine, conjugates
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antibodies specifically bind to anionic phospholipids and/or aminophospholipids conjugated with duramycin peptide for treating viral infections and cancer)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 7 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:41226 HCAPLUS
DN 140:105321
TI Methods and compositions relating to isoleucine boroproline compounds
IN Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PA Point Therapeutics, Inc., USA
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004004658	A2	20040115	WO 2003-US21405	20030709 <--
	WO 2004004658	A3	20050804		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2491466	AA	20040115	CA 2003-2491466	20030709 <--
	AU 2003265264	A1	20040123	AU 2003-265264	20030709 <--
	US 2004077601	A1	20040422	US 2003-616694	20030709 <--
	US 2005084490	A1	20050421	US 2003-616409	20030709 <--
	EP 1578434	A2	20050928	EP 2003-763380	20030709 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006507352	T2	20060302	JP 2004-562634	20030709 <--
PRAI	US 2002-394856P	P	20020709	<--	
	US 2002-414978P	P	20021001	<--	
	US 2003-466435P	P	20030428		
	WO 2003-US21405	W	20030709		

OS MARPAT 140:105321
AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptiolyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.
IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 8 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:971770 HCAPLUS
DN 140:27709
TI Preparation of phosphonic acid based prodrugs of phosphonylmethoxyethyladenine and its analogues for their therapeutic use as antiviral and anticancer agents
IN Reddy, K. Raja; Erion, Mark D.; Matelich, Michael C.; Kopcho, Joseph J.
PA USA
SO U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003229225	A1	20031211	US 2003-436922	20030512 <--
	CA 2485702	AA	20040506	CA 2003-2485702	20030512 <--
	WO 2004037161	A2	20040506	WO 2003-US14821	20030512 <--
	WO 2004037161	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299492	A1	20040513	AU 2003-299492	20030512 <--
	EP 1532157	A2	20050525	EP 2003-799779	20030512 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006511490 T2 20060406 JP 2004-546667 20030512 <--
PRAI US 2002-380545P P 20020513 <--
WO 2003-US14821 W 20030512
OS MARPAT 140:27709
GI



I II

AB The present invention discloses a method of preparing phosphonate cyclic esters, such as I [M and V are cis to one another; MPO3H2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxypropyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, 9-(2-phosphonylmethoxy ethyloxy)adenine, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, and (S)-9-(3-fluoro-2-phosphonyl methoxypropyl)adenine; V = Ph, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, optionally substituted with 1-3 substituents selected from a group consisting of F, Cl, Br, alkyl, CF3, OR6; R6 = alkyl, CF3], and pharmaceutically acceptable salts thereof for their therapeutic use as antiviral and anticancer agents. The process involves coupling of a chiral 1-phenylpropane-1,3-diol [Ph may be optionally substituted], with MPOCl2 or an N-6 substituted analog thereof. Addnl., methods and salt forms that enable isolation and purification of the desired isomer are also described. Thus, phosphonate cyclic ester derivative II.MeSO3H was prepared via a multistep reaction sequence starting from 3-chlorobenzoyl chloride, trimethylsilyl acetate, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), N,N-diethylformamide, oxalyl chloride and methanesulfonic acid. Other examples include activation of phosphoramidate prodrugs by human microsomes and the identification and tissue distribution of the microsomal enzymes involved in activation.

IT **181785-84-2**, ACH 126443
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(together with phosphonate cyclic esters of phosphonylmethoxyethyladenine for their therapeutic use as antiviral agents)
RN 181785-84-2 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L37 ANSWER 9 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:590943 HCAPLUS
DN 139:154893
TI Phthalocyanine and porphyrazine pharmaceutical compositions
IN Compans, Richard W.; Marzilli, Luigi G.; Dixon, Dabney W.
PA Emory University, USA; Georgia State University Research Foundation, Inc.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003061579	A2	20030731	WO 2003-US1619	20030117 <--
WO 2003061579	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-349944P P 20020118 <--
OS MARPAT 139:154893
AB Pharmaceutical compns. containing a neutral or neg. charged compound having a phthalocyanine structure or one of the porphyrazines or the metal-complex formed thereof are effective in decreasing infection by HIV and other pathogens leading to sexually transmitted diseases. The compns. can be made suitable for any mode of administration. Preferably, the composition is suitable for topical administration, especially for mucosal administration. The most preferred composition is suitable for vaginal or rectal administration.
IT **3056-17-5**, D4T **7481-88-1**, D 4C **7481-89-2**, DDC
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(co-administration with; mucosal and topical compns. containing phthalocyanines and porphyrazines for treatment of sexually transmitted diseases)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-88-1 HCAPLUS
CN Cytidine, 2',3'-didehydro-2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 10 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:551347 HCAPLUS
DN 139:111611
TI Porphyrins with virucidal activity, and use in the treatment of sexually transmitted diseases
IN Compans, Richard W.; Marzilli, Luigi G.; Sears, Amy E.; Dixon, Dabney W.
PA Emory University, USA; Georgia State University Research Foundation, Inc.
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057176	A2	20030717	WO 2003-US532	20030108 <--
	WO 2003057176	A3	20040916		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2472583	AA	20030717	CA 2003-2472583	20030108 <--
	AU 2003212790	A1	20030724	AU 2003-212790	20030108 <--
	EP 1480638	A2	20041201	EP 2003-708820	20030108 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005090428	A1	20050428	US 2003-500884	20030108 <--
PRAI	US 2002-347197P	P	20020108 <--		
	WO 2003-US532	W	20030108		

OS MARPAT 139:111611

AB Compns. and methods are provided for the prevention of sexually transmitted diseases resulting from infection with one or more viral pathogens. The compns. contain one or more porphyrins, tetrapyrrole macrocycle compds. with bridges of one carbon joining the pyrroles. In a preferred embodiment, the compns. are administered in a formulation suitable for administration to a mucosal surface.

IT **3056-17-5**, D4T **7481-88-1**, D 4C **7481-89-2**, DDC
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(porphyrins with virucidal activity, and use in the treatment of sexually transmitted diseases, and use with other agents)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-88-1 HCAPLUS
CN Cytidine, 2',3'-didehydro-2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 11 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:413956 HCAPLUS
DN 138:396187
TI Combination therapy involving drugs which target cellular proteins and drugs which target pathogen-encoded proteins for inhibiting replication of pathogens
IN Schaffer, Priscilla A.; Schang, Luis M.
PA USA
SO U.S. Pat. Appl. Publ., 76 pp., Cont.-in-part of U.S. Ser. No. 951,058.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003099944	A1	20030529	US 2000-905687	20001206 <--
	WO 2000006170	A1	20000210	WO 1999-US16252	19990716 <--
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1998-94805P	P	19980731 <--		
	US 1999-131264P	P	19990427 <--		
	US 1999-140926P	P	19990624 <--		
	WO 1999-US16252	A1	19990716 <--		
	US 2000-656592	A2	20000907 <--		
	US 2000-951058	A2	20000912 <--		

AB The invention relates to the identification of cdk inhibitors as inhibitors of pathogen gene expression, replication and reactivation. The invention also relates to the identification of a combination therapy to inhibit pathogen replication in which a drug that inhibits pathogen replication by targeting a specific pathogen-encoded protein is administered in combination with a drug that inhibits pathogen replication by targeting host-encoded cdk proteins. Compns. and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors. Vero cells (mammalian cell line) were infected with 3 PFUs of either a wild-type or an antiviral drug-resistant strain of HSV-1. One hour after infection, cultures were washed with PBS and then refed with medium containing acyclovir (ACV) and with cellular cyclin-dependent kinase inhibitors Roscovitine (Rosco) or Purvalanol (Purv). The effects of either Rosco or Purv on inhibiting viral replication, when used in combination with ACV, were greater than when either Rosco or Purv were used alone. Importantly, the increased effects of Rosco and Purv were observed during treatment of ACV-susceptible wild-type HSV-1 (KOS) and during treatment of an ACV-resistant strain (TK-) of HSV-1.

IT **3056-17-5**, Stavudine
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study);

USES (Uses)
(pathogen DNA replication inhibitor; combination therapy involving drugs which target cellular proteins and drugs which target pathogen-encoded proteins for inhibiting replication of pathogens)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L37 ANSWER 12 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:222146 HCAPLUS
DN 138:253701
TI Fusion proteins comprising transduction and cytotoxic domains for treating pathogenic infection
IN Dowdy, Steven F.
PA Washington University, USA
SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Provisional Ser. No. 82,402.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003054000	A1	20030320	US 2001-775052	20010201 <--
	US 6645501	B2	20031111		
	US 6221355	B1	20010424	US 1998-208966	19981210 <--
PRAI	US 1997-69012P	P	19971210 <--		
	US 1998-82402P	P	19980420 <--		

AB The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency. The pathogen includes cytomegalovirus, herpes simplex virus, **hepatitis C virus**, yellow fever virus, flavivirus, rhinovirus, HIV-1, HIV-2, HTLV-III, LAV, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, etc.
IT **3056-17-5**, d4T **7481-89-2**, DdC
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(fusion proteins comprising transduction and cytotoxic domains for treating viral, retroviral and plasmodial infections)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 13 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:128527 HCAPLUS
DN 138:395512
TI Efficacy of induction therapy with high-dose interferon for patients with hemophilia and human immunodeficiency virus-**hepatitis C virus** coinfection
AU Hanabusa, Hideji
CS Department of Hematology, Ogikubo Hospital, Tokyo, Japan
SO Clinical Infectious Diseases (**2002**), 35(12), 1527-1533
CODEN: CIDIEL; ISSN: 1058-4838
PB University of Chicago Press
DT Journal
LA English
AB To evaluate the efficacy of high-dose interferon (IFN) on human immunodeficiency virus (HIV) and **hepatitis C virus** (**HCV**) infection, 15 HIV-pos. patients and 15 age-matched HIV-neg. patients with hemophilia were treated with 9 million units (MU) of IFN-α2a daily for 2 wk, followed by 9 MU of IFN-α2a 3 times/wk for a further 22 wk. At week 2, HIV RNA levels decreased from 7410 ± 2190 to 320 ± 130 copies/mL, and **HCV** RNA levels decreased from 390 + 103 ± 80 + 103 to 70 + 103 ± 30 + 103 copies/mL in the HIV-pos. group and from 300 + 103 ± 80 + 103 to 10 + 103 ± 10 + 103 copies/mL in the HIV-neg. group. **HCV** RNA was undetectable after treatment in 4 of 12 HIV-pos. and 6 of 15 HIV-neg. patients. IFN therapy was discontinued because of adverse effects in 3 HIV-pos. patients. Induction therapy and the dose of IFN should be evaluated in combination therapy with IFN and ribavirin.
IT **3056-17-5**, Stavudine
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(efficacy of induction therapy with high-dose interferon-α2a for patients with hemophilia and HIV-**hepatitis C**

virus coinfection)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bain, V	2001	96	2818	Am J Gastroenterol	HCAPLUS
Cacciola, I	1999	341	22	N Engl J Med	MEDLINE
Cramp, M	2000	118	346	Gastroenterology	HCAPLUS
Daar, E	2001	183	589	J Infect Dis	MEDLINE
Darby, S	1997	350	1425	Lancet	MEDLINE
Eyster, M	1994	84	1020	Blood	MEDLINE
Eyster, M	1999	179	1062	J Infect Dis	MEDLINE
Fried, M	2000	95	3225	Am J Gastroenterol	HCAPLUS
Fukai, K	1998	178	325	J Infect Dis	HCAPLUS
Glue, P	2000	32	647	Hepatology	HCAPLUS
Hanabusa, H	1995		33	Abstract 19, Program	
Harrington, M	2000	355	2147	Lancet	MEDLINE
Ho, D	1995	333	450	N Engl J Med	MEDLINE
Hoggard, P	1997	41	1231	Antimicrob Agents Ch	HCAPLUS
Kuboki, M	2000	32	277A	Hepatology	
Lafeuillade, A	2001	357	280	Lancet	HCAPLUS
Lam, N	1997	26	226	Hepatology	HCAPLUS
Landau, A	2000	14	839	AIDS	HCAPLUS
Manns, M	2001	358	958	Lancet	HCAPLUS
Martinot-Peignoux, M	1995	22	1050	Hepatology	MEDLINE
McHutchison, J	1998	339	1485	N Engl J Med	HCAPLUS
Niro, G	1997	25	728	Hepatology	HCAPLUS
Okamoto, H	1997	78	737	J Gen Virol	HCAPLUS
Palella, F	1998	338	853	N Engl J Med	
Poynard, T	1996	24	778	Hepatology	HCAPLUS
Sabin, C	1997	175	164	J Infect Dis	MEDLINE
Sanchez-Quijano, A	1995	14	949	Eur J Clin Microbiol	MEDLINE
Seeff, L	1999	107	S10	Am J Med	
Shindo, M	2001	33	1299	Hepatology	HCAPLUS
Takayama, S	1999	104	626	Br J Haematol	MEDLINE

L37 ANSWER 14 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:53537 HCAPLUS
DN 138:105636
TI Stimulation of immune response with low doses of cytokines
IN Smith, Kendall A.
PA Cornell Research Foundation, Inc., USA
SO U.S., 21 pp., Cont.-in-part of U.S. 6,045,788.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6509313	B1	20030121	US 1996-646098	19960507 <--
	US 6045788	A	20000404	US 1996-608516	19960228 <--
	WO 9741831	A1	19971113	WO 1997-US7787	19970507 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9730613	A1	19971126	AU 1997-30613	19970507 <--
	EP 901370	A1	19990317	EP 1997-925488	19970507 <--
	R: DE, FR, GB, IT, NL, SE				
	JP 2000510122	T2	20000808	JP 1997-540196	19970507 <--
PRAI	US 1996-608516	A2	19960228 <--		
	US 1996-646098	A	19960507 <--		
	WO 1997-US7787	W	19970507 <--		

AB A method of activating the immune system of a subject comprises the chronic administration of low doses of an agent having cytokine activity, including natural and recombinant cytokines, fragments, analogs, fusion proteins, and derivs. thereof, that are pharmaceutically acceptable, and their mixts. with other biol. active agents and formulation ingredients. The agent is provided as a unit dosage form, in systemic and topical product form, as an implant, inhalant, transdermal delivery device, and ultrasound and electrotransport devices, as well as in the form of a kit for self-administration. The examples given include chronic administration of interleukin-2, interferon γ, joint antiviral/interferon γ therapy, derivatized and mutated interferon γ, interleukin-15, CD40 ligand, natural interferon α2, and interferon β.

IT **3056-17-5**, d4T **7481-89-2**, DDC
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(immune response stimulation with low doses of cytokines)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1984			EP 0118977	HCAPLUS
Anon	1988			EP 0254593	HCAPLUS
Anon	1988			WO 8803411	HCAPLUS
Anon	1990			EP 0353910	HCAPLUS
Anon	1990			EP 0378171	HCAPLUS
Anon	1990			WO 9014432	HCAPLUS
Anon	1991			EP 0405315	HCAPLUS
Anon	1991			WO 9101143	HCAPLUS
Anon	1992			WO 9205256	HCAPLUS
Anon	1992			WO 9208792	HCAPLUS
Anon	1992			WO 9213568	HCAPLUS
Anon	1993			EP 0533416	HCAPLUS
Anon	1995			EP 0640336	HCAPLUS
Anon	1995			WO 9527722	HCAPLUS
Anon	1996			WO 9604013	HCAPLUS
Anon	1996			WO 9630515	HCAPLUS
Anon	1996			WO 9636350	HCAPLUS
Bernstein, Z	1995	86	3287	Blood	HCAPLUS
Gough	1993			US 5208018 A	HCAPLUS
Grabstein	1995			US 5474769 A	HCAPLUS
Grimm	1993			US 5229109 A	HCAPLUS
Hedy, T	1993	167	291	The Journal of Infec	
Hershenson	1991			US 5004605 A	HCAPLUS
Howard	1990			US 4938956 A	HCAPLUS
Ihle, J	1996	84	331	Cell	HCAPLUS
Michael, A	1991	9	2110	Journal of Clinical	
Moriggl, R	1999	10	249	Immunity	HCAPLUS
Morikawa, K	1987	47	37	Cancer Research	HCAPLUS
Sibalis	1990			US 4940456 A	
Smith	2000			US 6045788 A	HCAPLUS
Smith, K	1995	766		Receptor Activation	HCAPLUS
Stewart	1993			US 5236707 A	HCAPLUS
Suto	1995			US 5420109 A	HCAPLUS
Tamblyn	1990			US 4933433 A	HCAPLUS
Ulich	1994			US 5376368 A	HCAPLUS
Von Eichborn	1992			US 5145677 A	HCAPLUS
Watowich, S	1996	12	91	Annu Rev Cell Dev Bi	HCAPLUS
Wiltrout	1992			US 5126129 A	HCAPLUS
Yang	1995	76	687	Cancer	MEDLINE
Yarchoan	1991			US 5026687 A	HCAPLUS

L37 ANSWER 15 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:947003 HCAPLUS
DN 138:29124
TI Time release reverse transcriptase inhibitors
IN Halstead, Bruce

PA USA
SO U.S. Pat. Appl. Publ., 3 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002187957	A1	20021212	US 2002-159417	20020529 <--
WO 2003101389	A2	20031211	WO 2003-US17131	20030529 <--
WO 2003101389	A3	20040513		
WO 2003101389	B1	20040624		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003238842	A1	20031219	AU 2003-238842	20030529 <--
US 2005129780	A1	20050616	US 2003-515773	20030529 <--
EP 1551419	A2	20050713	EP 2003-734301	20030529 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2001-294477P	P	20010530 <--		
US 2002-159417	A	20020529 <--		
US 2002-159433	A	20020529 <--		
US 2002-159434	A	20020529 <--		
US 2002-159723	A	20020529 <--		
US 2002-159747	A	20020529 <--		
US 2002-395227P	P	20020710 <--		
WO 2003-US17131	W	20030529		

AB A pharmaceutical composition comprises a reverse transcriptase inhibitor in a quantity sufficient to reduce a viral serum titer of a virus in an amount of at least 20% over a period of at least 6 h, wherein the preferred reverse transcriptase inhibitor comprises a plant extract The compns. further comprise a chelating agent, the chelating agent being present in a single dose in a concentration such that the serum Mg2+ and/or Ca2+ concentration is reduced at least 20% over a period of at least 6 h,.

IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(time release reverse transcriptase inhibitors)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 16 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:927626 HCAPLUS
DN 138:20431
TI Use of mitochondrial DNA-specific quantitative real-time PCR for diagnosis and monitoring drug toxicity in humans suffering with various disorders such as viral infections, neurological disorders, cancer, arthritis, male sterility or organ failure
IN Cote, Helene; Montaner, Julio; O'Shaughnessy, Michael V.
PA The University of British Columbia, Can.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002097124	A1	20021205	WO 2002-CA796	20020529 <--
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2416332	AA	20021205	CA 2002-2416332	20020529 <--
	US 2003099933	A1	20030529	US 2002-158543	20020529 <--
	EP 1395681	A1	20040310	EP 2002-729732	20020529 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004532043	T2	20041021	JP 2003-500289	20020529 <--

PRAI US 2001-293523P P 20010529 <--
WO 2002-CA796 W 20020529 <--

AB The invention discloses the use of quant. real-time **polymerase** chain reaction (PCR) to monitor drug toxicity, which involves measuring the relative amount of mitochondrial DNA in peripheral blood cells obtained from individuals suffering with various disorders. The invention relates that the quant. real-time PCR involves co-amplification of a mitochondrial sequence and a reference sequence, such as a genomic sequence. The invention also discloses that said disorders include HIV infection, cancer, **hepatitis** A, **hepatitis** B, **hepatitis C**, arthritis, Alzheimer's disease, Parkinson's disease, or Huntington's disease. The invention also relates that said drugs used to treat patients include nucleoside or nucleotide analogs, and/or reverse transcriptase inhibitors. The invention further discloses that the said method can be used to diagnose conditions such as male infertility and organ failure. The method was illustrated by detecting the amount of mitochondrial gene CCOI and the nuclear gene ASPOLγ in HIV infected individuals undergoing antiviral therapy.

IT **3056-17-5**, Stavudine **7481-89-2**, Hivid
RL: ADV (Adverse effect, including toxicity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(mitochondrial DNA-specific quant. real-time PCR for monitoring drug toxicity in individuals suffering for various disorders such as viral infections, neurol. disorders, cancer, and arthritis)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Arnaudo, E	1991	337	508	LANCET	MEDLINE
Berlin, K	1998	245	137	EXPERIMENTAL CELL RE	HCAPLUS

Brinkman, K	1999	354	1112	LANCET	HCAPLUS
Church, J	2001	138	748	JOURNAL OF PEDIATRIC	MEDLINE
Kakuda, T	2000	22	685	CLINICAL THERAPEUTIC	HCAPLUS
Kao, S	1998	4	657	MOLECULAR HUMAN REPR	HCAPLUS
Lewis, W	1997	76	77	LABORATORY INVESTIGA	HCAPLUS
Medina, D	1994	38	1824	ANTIMICROBIAL AGENTS	HCAPLUS
Mitokor	2001			WO 0135096 A	HCAPLUS
The Regents Of The Univ	2000			WO 0050043 A	HCAPLUS

L37 ANSWER 17 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:832613 HCAPLUS
DN 137:333119
TI 3-Aminopyridine-2-carboxyaldehyde thiosemicarbazones and methods using them for treating viral and fungal infections
IN King, Ivan C.; Doyle, Terrence W.; Sznol, Mario; Sartorelli, Alan C.; Cheng, Yung-Chi
PA Vion Pharmaceuticals, Inc., USA; Yale University
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085358	A2	20021031	WO 2002-US12358	20020418 <--
	WO 2002085358	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002188011	A1	20021212	US 2002-126050	20020418 <--
	US 6911460	B2	20050628		
	CN 1503669	A	20040609	CN 2002-808591	20020418 <--
	US 2005261251	A1	20051124	US 2005-93648	20050330 <--
PRAI	US 2001-285559P	P	20010420 <--		
	US 2002-126050	A3	20020418 <--		

OS MARPAT 137:333119
AB The invention provides methods for treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP), and prodrug forms thereof, as well as pharmaceutical compns. comprising these compds. Preparation of compds. of the invention is described.
IT **3056-17-5 3416-05-5**, 2',3'-Dideoxythymidine
7481-88-1 7481-89-2, 2',3'-Dideoxycytidine
135212-57-6 147058-39-7 181785-84-2
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(aminopyridinecarboxyaldehyde thiosemicarbazones for treatment of viral and fungal infections)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 3416-05-5 HCAPLUS
CN Thymidine, 3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 7481-88-1 HCAPLUS
CN Cytidine, 2',3'-didehydro-2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 135212-57-6 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 147058-39-7 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 181785-84-2 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L37 ANSWER 18 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:570135 HCAPLUS
DN 137:134544
TI Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy
AU Wit, Ferdinand W. N. M.; Weverling, Gerrit Jan; Weel, Jan; Jurriaans, Suzanne; Lange, Joep M. A.
CS National AIDS Therapy Evaluation Center, Departments of Human Retrovirology, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Neth.
SO Journal of Infectious Diseases (**2002**), 186(1), 23-31
CODEN: JIDIAQ; ISSN: 0022-1899
PB University of Chicago Press

DT Journal
LA English
AB This retrospective cohort study investigated whether particular antiretroviral agents are associated with a higher risk for developing grade 4 liver enzyme elevations (LEEs) in patients with human immunodeficiency virus (HIV) type 1 infection who are starting to receive highly active antiretroviral therapy (HAART). Grade 4 LEE was defined as aminotransferase levels >10 times the upper limit of normal and >200 U above baseline levels. A multivariate Cox model was used to identify risk factors. The incidence of LEE was 6.3%. No patients died of LEE consequences. Risk factors were higher baseline alanine aminotransferase levels, chronic **hepatitis** B or C virus infection, antiretroviral therapy-naive patients undergoing their first HAART regimen, recent start of a regimen of nevirapine or high-dose ritonavir, and female sex. In **hepatitis** B virus (HBV)-coinfected patients, discontinuing lamivudine (3TC) use was a risk factor. In 97% of cases, ≥ 1 risk factor was present. In HBV coinfected patients using 3TC, continued use of 3TC should be considered, even if 3TC-resistant HIV strains develop.
IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: ADV (Adverse effect, including toxicity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	2000	9	116	Prescrire Int	
de Requena, G	2002	16	290	AIDS	
Dieterich, D	2001			[Abstract 44], Progr	

Martinez, E	2001	15	1261	AIDS	HCAPLUS
Reisler, R	2001			[Abstract 43], Progr	

L37 ANSWER 19 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:521407 HCAPLUS
DN 137:73237
TI Single and combination therapy using drugs with target cellular proteins and drugs which target pathogen-encoded proteins
IN Schaffer, Priscilla A.; Schang, Luis M.
PA The Trustees of the University of Pennsylvania, USA
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053096	A2	20020711	WO 2001-US47257	20011206 <--
	WO 2002053096	A3	20030130		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2002245081	A1	20020716	AU 2002-245081	20011206 <--
PRAI	US 2000-251623P	P	20001206 <--		
	US 2000-251653P	P	20001206 <--		
	WO 2001-US47257	W	20011206 <--		

AB The invention relates to the identification of cdk inhibitors as inhibitors of pathogen gene expression, replication and reactivation. The invention also relates to the identification of a combination therapy to inhibit pathogen replication in which a drug that inhibits pathogen replication by targeting a specific pathogen-encoded protein is administered in combination with a drug that inhibits pathogen replication by targeting host-encoded cdk proteins. Compns. and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors.
IT **3056-17-5**, Stavudine
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(drugs with target cellular proteins and drugs which target pathogen-encoded proteins for single and combination therapy)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L37 ANSWER 20 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:395261 HCAPLUS
DN 137:15339

TI Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with **hepatitis C virus** and human immunodeficiency virus

AU Cooper, Curtis L.; Parbhakar, M. A.; Angel, Jonathan B.
CS Division of Infectious Diseases, Ottawa Hospital Research Institute, University of Ottawa, ON, Can.

SO Clinical Infectious Diseases (**2002**), 34(9), 1259-1263
CODEN: CIDIEL; ISSN: 1058-4838
PB University of Chicago Press
DT Journal
LA English

AB The aim of this study was to determine the rates of patients coinfected with human immunodeficiency virus (HIV) and **hepatitis C virus** (**HCV**) who discontinued therapy as a result of protease inhibitor (PI)-related hepatotoxicity, a retrospective review was conducted. Baseline CD4 counts, plasma HIV RNA levels, and duration of therapy were comparable between single- and dual-PI-treated subjects and between subjects receiving ritonavir-containing therapy and those receiving ritonavir-sparing therapy. The proportions of patients with elevations in alanine aminotransferase level to ≥5 times the upper limit of normal (19% vs. 26%) and hyperbilirubinemia (30% vs. 38%) were similar between the dual-PI (n = 27) and single-PI treatment groups (n = 39), resp. No difference in these characteristics was observed between ritonavir-containing (n = 34) and ritonavir-sparing (n = 32) treatment arms. Rates of treatment discontinuation due to hepatotoxicity were similar for single-PI and dual-PI therapy and for ritonavir-containing and ritonavir-sparing regimens. Dual-PI therapy and inclusion of ritonavir do not seem to increase the rates of hepatotoxicity in PI-treated, HIV-**HCV** coinfected subjects.

IT **3056-17-5**, Stavudine
RL: ADV (Adverse effect, including toxicity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(hepatotoxicity associated with antiretroviral therapy containing dual vs. single protease inhibitors in individuals coinfected with **hepatitis C virus** and human immunodeficiency virus)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bica, I	2001	32	492	Clin Infect Dis	MEDLINE
Bonacini, M	2000	160	3365	Arch Intern Med	MEDLINE
Brau, N	1997	349	924	Lancet	MEDLINE

Cameron, D	1999	13	213	AIDS	HCAPLUS
Cameron, D	1998	351	543	Lancet	HCAPLUS
Carr, A	2001	357	1412	Lancet	MEDLINE
Den Brinker, M	1998			Program and abstract	
Gerard, Y	2000	14	2723	AIDS	HCAPLUS
Gisolf, E	2000	31	1234	Clin Infect Dis	HCAPLUS
Gulick, R	1997	337	734	N Engl J Med	HCAPLUS
Johri, S	2000	14	1286	AIDS	MEDLINE
Melvin, D	2000	14	463	AIDS	MEDLINE
Miller, K	2000	133	192	Ann Intern Med	MEDLINE
National Institutes of	1992			ACTG criteria: table	
Puoti, M	2000	24	211	J Acquir Immune Defi	HCAPLUS
Rockstroh, J	2000	14	1181	AIDS	HCAPLUS
Saves, M	1999	13	F115	AIDS	HCAPLUS
Saves, M	2000	44	3451	Antimicrob Agents Ch	HCAPLUS
Sulkowski, M	2000	283	74	JAMA	HCAPLUS
Vento, S	1998	12	116	AIDS	MEDLINE
Workman, C	1999		195	Program and abstract	
Zucker, S	2001	98	12671	PNAS	HCAPLUS

L37 ANSWER 21 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:314958 HCAPLUS
DN 136:340939
TI Preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation
IN Stuyver, Lieven; Watanabe, Kyoichi A.
PA **Pharmasset Limited, USA**
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032920	A2	20020425	WO 2001-US46113	20011018 <--
	WO 2002032920	A3	20040219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2426187	AA	20020425	CA 2001-2426187	20011018 <--
	AU 2002028749	A5	20020429	AU 2002-28749	20011018 <--
	US 2003087873	A1	20030508	US 2001-45292	20011018 <--
	EP 1411954	A2	20040428	EP 2001-987756	20011018 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2004533406	T2	20041104	JP 2002-536301	20011018 <--
	CN 1646141	A	20050727	CN 2001-820816	20011018 <--
	BR 2001014837	A	20060509	BR 2001-14837	20011018 <--
PRAI	US 2000-241488P	P	20001018 <--		
	US 2001-282156P	P	20010406 <--		
	WO 2001-US46113	W	20011018 <--		

OS MARPAT 136:340939
GI



I

AB Modified nucleosides, e.g. I, wherein D is hydrogen, alkyl, acyl, monophosphate, diphosphate, triphosphate, monophosphate ester, diphosphate ester, triphosphate ester, phospholipid or amino acid; X is H, halogen, NH2, substituted amine, oxime, OH, alkoxy, SH, thioalkyl; Y is O, S, Se; R and R1 are independently H, alkyl, alkenyl, alkynyl, aryl, alkylaryl, halogen, NH2, substituted amine, oxime, hydrazine, OH, alkoxy, SH, thioalkyl, NO2, NO, CH2OH, CH2OH, ester, CONH2, amide, CN; R2 and R3 are independently H, halogen, OH, SH, OMe, SMe, NH2, NHMe, CH:CH2, CN, CH2NH2, CH2OH, CO2H; were prepared for treating a Flaviviridae (including BVDV and **HCV**), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans. This invention also provides an effective process to quantify the viral load, and in particular BVDV, **HCV** or West Nile Virus load, in a host, using real-time **polymerase** chain reaction ("TR-PCR"). Addnl., the invention discloses probe mols. that can fluoresce proportionally to the amount of virus present in a sample. Thus, (1'R,2'S,3'R,4'R)-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentan-1-yl]-5-fluorocytosine was prepared and tested in vitro as antiviral and antitumor agent.

IT **241806-22-4P 241806-28-0P 415705-39-4P**
415705-40-7P 415705-43-0P 415705-44-1P
RL: IMF (Industrial manufacture); **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation)

RN 241806-22-4 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[(1R,3S)-3-(hydroxymethyl)cyclopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 241806-28-0 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(1R,3S)-3-(hydroxymethyl)cyclopentyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415705-39-4 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(1S,3R)-3-(hydroxymethyl)cyclopentyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415705-40-7 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(1S,3R)-3-(hydroxymethyl)cyclopentyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415705-43-0 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(1S,3R)-3-(hydroxymethyl)cyclopentyl]-5-
iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415705-44-1 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(1R,3S)-3-(hydroxymethyl)cyclopentyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 22 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:171918 HCAPLUS
DN 136:217007
TI Preparation of antiviral nucleoside derivatives as inhibitors of subgenomic **hepatitis C virus** RNA replication
IN Devos, Rene; Dymock, Brian William; Hobbs, Christopher John; Jiang, Wen-rong; Martin, Joseph Armstrong; Merrett, John Herbert; Najera, Isabel; Shimma, Nobuo; Tsukuda, Takuo
PA F. Hoffmann-La Roche Ag, Switz.
SO PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018404	A2	20020307	WO 2001-EP9633	20010821 <--
WO 2002018404	C2	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003008841	A1	20030109	US 2001-923620	20010807 <--
CA 2419399	AA	20020307	CA 2001-2419399	20010821 <--

	AU 2001095497	A5	20020313	AU 2001-95497	20010821 <--
	EP 1315736	A2	20030604	EP 2001-976128	20010821 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013611	A	20030624	BR 2001-13611	20010821 <--
	JP 2004513083	T2	20040430	JP 2002-523918	20010821 <--
	ZA 2003001540	A	20040621	ZA 2003-1540	20030225 <--
	US 2004110718	A1	20040610	US 2003-678804	20031003 <--
PRAI	GB 2000-21285	A	20000830 <--		
	GB 2000-26611	A	20001031 <--		
	US 2001-923620	B1	20010807 <--		
	WO 2001-EP9633	W	20010821 <--		

OS MARPAT 136:217007

GI



I



II

AB Nucleosides I , wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, S or CH2; B is a substituted purine base, were prepared as inhibitors of subgenomic **hepatitis C virus** (**HCV**) RNA replication. Thus, nucleoside II was prepared and tested for the inhibition of **HCV** RNA replication (EC50 = 0.6 μM).

IT **7481-89-2P 121154-57-2P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antiviral nucleoside derivs. as inhibitors of subgenomic **hepatitis C virus** RNA replication)

RN 7481-89-2 HCAPLUS

CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 121154-57-2 HCAPLUS
CN Thymidine, 3'-deoxy-5'-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 23 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:109650 HCAPLUS
DN 136:288583
TI Effects of HAART on **hepatitis C, hepatitis** G, and TT virus in multiply coinfected HIV-positive patients with haemophilia
AU Takamatsu, J.; Toyoda, H.; Fukuda, Y.; Nakano, I.; Yokozaki, S.; Hayashi, K.; Saito, H.
CS Department of Transfusion Medicine, Nagoya University School of Medicine, Nagoya, 466-8550, Japan
SO Haemophilia (**2001**), 7(6), 575-581
CODEN: HAEMF4; ISSN: 1351-8216
PB Blackwell Science Ltd.
DT Journal
LA English
AB In multiply coinfected human immunodeficiency virus (HIV)-pos. patients, we investigated the effects of high-activity antiretroviral therapy (HAART) using HIV protease inhibitors on three other viruses: **hepatitis C virus** (**HCV**), **hepatitis** G virus (HGV), and TT virus (TTV). Viral concns. were measured serially by **polymerase** chain reaction methods in five patients with quadruple infection (HIV, **HCV**, HGV, and TTV) and in two patients with triple infection (HIV, **HCV**, and HGV) before and during HAART. In addition, CD4+ cell counts and serum alanine aminotransferase (ALT) levels were measured serially. Generally we observed no difference in serum **HCV** RNA, HGV RNA, or TTV DNA concns. between samples obtained before and after initiation of HAART, whereas HIV RNA concentration decreased and CD4 counts increased in most patients. However, two patients had markedly decreased concns. of **HCV** RNA and HGV RNA, resp., more than 12 mo after beginning HAART. Normalization of serum ALT levels was observed in a patient with decline of **HCV** RNA concns. No interactions were observed among these four viruses. HAART had no apparent direct effects on **HCV**, HGV, or TTV. Further studies will be required to elucidate whether the restoration of immune status through suppression of HIV replication by HAART may affect **HCV** or HGV RNA concns.
IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(HAART effect on **hepatitis C, hepatitis** G, and TT virus in HIV-pos. patients with multiple coinfections and haemophilia)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Carpenter, C	1996	276	146	J Am Med Assoc	MEDLINE
Carr, A	1997	349	995	Lancet	MEDLINE
Collier, A	1996	334	1011	N Engl J Med	HCAPLUS
Cribier, B	1995	9	1131	AIDS	HCAPLUS
De Milito, A	1999	57	140	J Med Virol	HCAPLUS
Devereux, H	1998	56	316	J Med Virol	MEDLINE
Dille, B	1997	175	458	J Infect Dis	HCAPLUS
Eyster, M	1994	84	1020	Blood	MEDLINE
Fialaire, P	1999	180	574	J Infect Dis	MEDLINE
Garcia-Samaniego, J	1998	28	526	J Hepatol	MEDLINE
Goubau, P	1999	57	367	J Med Virol	MEDLINE
Hammer, S	1997	337	725	N Engl J Med	HCAPLUS
Hanley, J	1998	79	291	Thromb Haemost	HCAPLUS
Heid, C	1996	6	986	Genome Res	HCAPLUS
Inoue, K	1999	30	801	J Hepatol	MEDLINE
Kato, T	2000	38	94	J Clin Microbiol	HCAPLUS
Kato, T	1998	55	109	J Med Virol	HCAPLUS
Kihara, M	1997	14	S3	J Acq Immun Def Synd	
Kinoshita, T	1997	175	454	J Infect Dis	MEDLINE
Linnen, J	1996	271	505	Science	HCAPLUS
Lipsky, J	1996	348	800	Lancet	HCAPLUS
Markowitz, M	1995	333	1534	N Engl J Med	HCAPLUS
Muerhoff, A	1996	25	379	J Hepatol	HCAPLUS
Mushahwar, I	1999	96	3177	Proc Natl Acad Sci U	HCAPLUS
Nakao, H	1997	233	43	Virology	HCAPLUS
Nishizawa, T	1997	241	92	Biochem Biophys Res	HCAPLUS

Okamoto, H	1998	10	1	Hepatol Res	
Okamoto, H	1996	57	31	J Virol Meth	HCAPLUS
Okamoto, H	1990	60	215	Jpn J Exp Med	MEDLINE
Perez-Olmeda, M	2000	14	212	AIDS	MEDLINE
Prescott, L	1998	339	776	N Engl J Med	MEDLINE
Rizzieri, D	1997	349	775	Lancet	MEDLINE
Rockstroh, J	1998	12	829	AIDS	MEDLINE
Rutschmann, O	1998	177	783	J Infect Dis	HCAPLUS
Simmonds, P	1994	19	1321	Hepatology	MEDLINE
Simons, J	1995	1	564	Nat Med	HCAPLUS
Tacke, M	1997	349	318	Lancet	HCAPLUS
Takahashi, K	1998	12	233	Hepatol Res	
Takayama, S	1999	104	626	Br J Haematol	MEDLINE
Tanaka, T	1999	57	370	J Med Virol	HCAPLUS
Thomas, D	1998	177	539	J Infect Dis	MEDLINE
Toyoda, H	1999	29	1332	Clin Infect Dis	MEDLINE
Toyoda, H	1999	38	198	J Infect	MEDLINE
Toyoda, H	1998	80	242	Thromb Haemost	HCAPLUS
Yokozaki, S	2000	96	4293	Blood	HCAPLUS
Yokozaki, S	1999	105	1114	Br J Haematol	MEDLINE
Zuckerman, A	1996	347	558	Lancet	MEDLINE
Zuckerman, A	1999	353	932	Lancet	MEDLINE
Zylberberg, H	1998	26	1104	Clin Infect Dis	MEDLINE

L37 ANSWER 24 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:107667 HCAPLUS
DN 136:145568
TI Improved tolerance to anti-viral and anti-tumor chemotherapy by administration of erythropoietin
IN Itri, Loretta; Bowers, Peter
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010743	A1	20020207	WO 2001-US24426	20010801 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2417550	AA	20020207	CA 2001-2417550	20010801 <--
	US 2002052317	A1	20020502	US 2001-921516	20010801 <--
	EP 1325324	A1	20030709	EP 2001-959497	20010801 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004505114	T2	20040219	JP 2002-516619	20010801 <--
	BR 2001013179	A	20040622	BR 2001-13179	20010801 <--
	ZA 2003001634	A	20040622	ZA 2003-1634	20030227 <--
PRAI	US 2000-222538P	P	20000802 <--		
	WO 2001-US24426	W	20010801 <--		

AB The present invention provides methods using erythropoietin to improve the tolerance of anti-viral and anti-tumor chemotherapeutic regimens containing

interferon. The invention also described improved methods to treat chronic **HCV** by adjusting the dose of ribavirin to tailor the active dose of the drug while supporting the Hb levels in the patient with EPO. The present invention also provides anti-viral dosing regimens, particularly for chronic **HCV** comprising administration of an interferon containing anti-viral medicament, EPO, and a compound that reduces the amount of active tumor necrosis factor in the subject.

IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: ADV (Adverse effect, including toxicity); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(improved tolerance to anti-viral and anti-tumor chemotherapy by administration of erythropoietin)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Akpek, G	1999	86	1368	Lymphoma	HCAPLUS
Aviles, A	1995	10	273	Cancer Biother	HCAPLUS
Bajorin, D	2000	88	1671	Cancer	HCAPLUS
Bourantas, K	1996	96	79	Acta Haematol	HCAPLUS
Cortes, J	1996	100	452	American Journal of	MEDLINE
Hilbe, W	1999	102	99	Acta Haematol	HCAPLUS
Hinotsu, S	1999	86	1818	Cancer	MEDLINE
McPherson, E	2000	96	7B	Suppression of Hepat	
Naglieri, E	1998	3B	2021	Anticancer Research	
Peuckmann, V	2000	60	273	Drugs	HCAPLUS
Pronzato, P	1995	15	2679	Anticancer Res	HCAPLUS
Reichard, O	1997	26	108S	Hepatology	
Tetreault, S	1999	35	347	Leukemia and Lymphom	MEDLINE

Trimble, E |2000 |27 |24 |Seminars in Oncology|MEDLINE

L37 ANSWER 25 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:69299 HCAPLUS
DN 136:272695
TI Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of **hepatitis C** and B infections
AU Sulkowski, Mark S.; Thomas, David L.; Mehta, Shruti H.; Chaisson, Richard E.; Moore, Richard D.
CS Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA
SO Hepatology (Philadelphia, PA, United States) (**2002**), 35(1), 182-189
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
AB Hepatologists are frequently asked to evaluate human immunodeficiency virus (HIV)-infected patients with abnormal liver enzymes and to assess the causal role of medications, such as antiretroviral drugs. Recently, the use of HIV-1 specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), including nevirapine (NVP) and efavirenz (EFV), has been associated with severe hepatic injury. We prospectively studied the incidence of severe hepatotoxicity (grade 3 or 4 change in alanine or aspartate transaminase levels) among 568 patients receiving NNRTI-containing antiretroviral therapy, including 312 and 256 patients prescribed EFV and NVP, resp. **Hepatitis C virus** (**HCV**) and **hepatitis** B virus (HBV) were detected in 43% and 7.7% of patients, resp. Severe hepatotoxicity was observed in 15.6% of patients prescribed NVP and 8.0% of those prescribed EFV, but only 32% of NVP and 50% of EFV-associated episodes were detected during the first 12-wk of therapy. The risk was significantly greater among persons with chronic viral **hepatitis** (69% of cases) and those prescribed concurrent protease inhibitors (PIs) (82% of cases). Nonetheless, 84% of patients with chronic **HCV** or HBV did not experience severe hepatotoxicity. Severe hepatotoxicity occurs throughout the course of NNRTI therapy and is more common among patients prescribed nevirapine, those coinfected with **HCV** or HBV, and those coadministered protease inhibitors.
IT **3056-17-5**, Stavudine
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nevirapine- or efavirenz-containing antiretroviral therapy: hepatotoxicity in HIV patients infected with HBV or **HCV**)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Albrecht, M	2001	345	398	N Engl J Med	HCAPLUS
Antinori, A	2001	15	1579	AIDS	HCAPLUS
Bartlett, J	2001			Program and abstract	
Benhamou, Y	1999	30	1054	Hepatology	MEDLINE
Bersoff-Matcha, S	2001	32	124	Clin Infect Dis	MEDLINE
Brau, N	1997	349	924	Lancet	MEDLINE
Carr, A	2001	357	1412	Lancet	MEDLINE
Cattelan, A	1999	29	455	Clin Infect Dis	MEDLINE
Clarke, S	2000	31	806	Clin Infect Dis	MEDLINE
den Brinker, M	2000	14	2895	AIDS	HCAPLUS
Dieterich, D	2001			1st Internationa	
Dupont Pharmaceuticals	2000			Efavirenz (Sustiva)	
D'Aquila, R	1996	124	1019	Ann Intern Med	HCAPLUS
Fagot, J	2001	15	1843	AIDS	MEDLINE
Fiske, W	1999			Program and abstract	
Haas, D	2001	183	392	J Infect Dis	HCAPLUS
John, M	1998	12	2289	AIDS	HCAPLUS
Johnson, S	2000	284	2722	JAMA	MEDLINE
Kronenberg, A	2001	358	759	Lancet	MEDLINE
Lucas, G	2001	15	1679	AIDS	HCAPLUS
Martinez, E	2001	15	1261	AIDS	HCAPLUS
Marzolini, C	2001	15	71	AIDS	HCAPLUS
Maserati, R	1999	13	870	AIDS	MEDLINE
Miguez-Burbano, M	2001			1st Internationa	
Miwa, L	1997	157	2129	Arch Intern Med	MEDLINE
Monga, H	2001	33	240	Clin Infect Dis	MEDLINE
Montaner, J	1998	279	930	JAMA	HCAPLUS
Moore, R	1994	330	763	N Engl J Med	MEDLINE
Moyle, G	2001	61	19	Drugs	HCAPLUS
Nunez, M	2001	27	426	J Acquir Immune Defi	HCAPLUS
Palella, F	1998	338	853	N Engl J Med	
Palmon, R	2000	32	312A	Hepatology	
Perrillo, R	1986	105	382	Ann Intern Med	MEDLINE
Peytavin, G	2001			1st Internationa	
Pollard, R	1998	20	1071	Clin Ther	HCAPLUS
Prakash, M	2001	96	1571	Am J Gastroenterol	MEDLINE
Ragni, M	1999	180	2027	J Infect Dis	MEDLINE
Reisler, R	2001			1st Internationa	
Rey, D	2001	27	459	J Acquir Immune Defi	HCAPLUS
Rodriguez-Rosado, R	1998	12	1256	AIDS	MEDLINE
Roxane Laboratories Inc	2000			Nevirapine (Viramune	
Rutschmann, O	1998	177	783	J Infect Dis	HCAPLUS
Saves, M	1999	13	F115	AIDS	HCAPLUS
Sha, B	2000	284	2723	JAMA	MEDLINE
Staszewski, S	1999	341	1865	N Engl J Med	HCAPLUS
Sulkowski, M	2000	30	S77	Clin Infect Dis	
Sulkowski, M	2000	283	74	JAMA	HCAPLUS
Thomas, D	2000	284	450	JAMA	MEDLINE
Verdon, R	2001	34	783	J Hepatol	MEDLINE
Veronese, L	2000	44	821	Antimicrob Agents Ch	HCAPLUS
von Moltke, L	2001	41	85	J Clin Pharmacol	HCAPLUS
Zylberberg, H	1996	23	1117	Clin Infect Dis	MEDLINE

L37 ANSWER 26 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:935354 HCAPLUS

DN 136:64094
TI The use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites, and precursors thereof in the treatment of viral infections
IN Prendergast, Patrick Thomas
PA Kotze, Gavin Salomon, S. Afr.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001097749	A2	20011227	WO 2001-IB1101	20010622 <--
	WO 2001097749	A3	20020523		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001074383	A5	20020102	AU 2001-74383	20010622 <--
PRAI	IE 2000-511	A	20000623 <--		
	IE 2001-275	A	20010321 <--		
	WO 2001-IB1101	W	20010622 <--		

AB The invention discloses the use of synthetic, non-hormonal 21-aminosteroids, derivs., metabolites, and precursors thereof in the treatment of viral infections, particularly **hepatitis** and retroviral infection by HIV. Synthetic non-hormonal 21-aminosteroids are disclosed for use in the prophylaxis and therapy of **hepatitis** viral infections. These compds. can be administered alone or in combination with conventional antiviral agents.

IT **3056-17-5**, d4T **7481-89-2**, DdC
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(aminosteroids, derivs., metabolites, and precursors for treatment of viral infection, and use with other agents)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 27 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:866574 HCAPLUS
DN 136:177515
TI Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy
AU Look, Markus P.; Riezler, Reiner; Berthold, Heiner K.; Stabler, Sally P.; Schliefer, Kirsten; Allen, Robert H.; Sauerbruch, Tilman; Rockstroh, Jurgen K.
CS Department of Internal Medicine I, University of Bonn, Bonn, 53105, Germany
SO Metabolism, Clinical and Experimental (**2001**), 50(11), 1275-1281
CODEN: METAAJ; ISSN: 0026-0495
PB W. B. Saunders Co.
DT Journal
LA English
AB This study investigates fasting serum levels of methionine and related metabolites, vitamin B6, and folate during highly active antiretroviral therapy in therapy-naive human immunodeficiency virus (HIV)-1-infected outpatients. The research design consisted of before and during therapy measurements with a median treatment period of 100 days (range, 50 to 188) in frozen samples. The subjects included 17 consecutive HIV-1-infected outpatients (15 men and 2 women; 25 to 65-yr-old). Controls were 42 healthy individuals (28 men and 14 women; 24- to 82-yr-old) without serol. evidence of HIV and/or **hepatitis C** infection and normal clin. chemical Subjects received treatment with the reverse transcriptase inhibitors, azidothymidine (AZT) or stavudine (D4T) plus lamivudine (3TC) and either the protease inhibitors, indinavir (IND), nelfinavir (NELF), ritonavir (RITV), or saquinavir (SAQ) at the standard dosage. Serum concns. of methionine, total homocysteine (tHcy), cystathionine (CYSTA), N,N-dimethylglycine (DMG), N-methylglycine (MG), methylmalonic acid (MMA), and total cysteine, as well as vitamin B6, folate, and soluble tumor necrosis factor receptor p75 were taken at baseline and during highly active antiretroviral therapy. Baseline, serum tHcy, MMA, CYSTA, vitamin B6 concns. were not significantly different from healthy controls. There was, however, a trend towards lower folate serum concns. at baseline in HIV-infected patients as compared with healthy controls (P =.06). There were no significant correlations between tHcy and vitamin B6, folate, or MMA. Elevated baseline levels of DMG and MG decreased significantly during antiretroviral therapy (P =.0019 and.04, resp.), whereas no significant changes in serum concns. of CYSTA, MMA, or methionine were detected. THcy increased in 12 of 17 patients (P =.09). HIV-infected patients displayed significant alterations (elevated DMG and MG serum concns.) in metabolite levels of the betaine pathway in methionine metabolism, which might be pos. influenced by newly initiated antiretroviral combination therapy.
IT **3056-17-5**, Stavudine
RL: ADV (Adverse effect, including toxicity); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(levels of methionine and related metabolites, vitamin B6 and folate in HIV-infected humans during short-term highly active antiretroviral therapy)

RN 3056-17-5 HCAPLUS

CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Akerlund, B	1996	50	457	Eur J Clin Pharmacol	MEDLINE
Allen, R	1993	42	1448	Metabolism	HCAPLUS
Baum, M	1991	4	1122	J Acquir Immune Defi	MEDLINE
Behrens, G	1999	13	63	AIDS	
Berthold, H	1999	246	567	J Intern Med	HCAPLUS
Breitkreutz, R	2000	16	203	AIDS Res Hum Retrovi	HCAPLUS
Buhl, R	1989	2	1294	Lancet	MEDLINE
Burgunder, J	1987	17	408	Eur J Clin Invest	MEDLINE
Cameron, D	1998	351	543	Lancet	HCAPLUS
Carpenter, C	1998	280	78	JAMA	HCAPLUS
Carr, A	1998	351	1881	Lancet	HCAPLUS
Castagna, A	1995	45	1678	Neurology	MEDLINE
Centers For Disease Con	1993	41	1	MMWR Morb Mortal Wkl	
Christeff, N	1999	13	2251	AIDS	HCAPLUS
Corrales, F	1991	14	528	Hepatology	HCAPLUS
de Quay, B	1992	6	305	AIDS	
den Heijer, M	1996	334	759	N Engl J Med	MEDLINE
Eck, H	1989	370	101	Biol Chem Hoppe-Seyl	HCAPLUS
Eikelboom, J	1999	131	363	Ann Intern Med	HCAPLUS
Folsom, A	1998	98	204	Circulation	HCAPLUS
Fugakawa, N	1998	68	380	Am J Clin Nutr	
Gallet, B	1998	351	1958	Lancet	MEDLINE
Henry, K	1998	351	1328	Lancet	MEDLINE
Hortin, G	1994	40	785	Clin Chem	MEDLINE
Kang, S	1991	48	536	Am J Hum Genet	MEDLINE
Keating, J	1991	337	935	Lancet	MEDLINE
Laurichesse, H	1998	128	1342	J Nutr	HCAPLUS
Lo, J	1998	351	867	Lancet	MEDLINE
Loguerico, C	1994	29	597	Alcohol Alcohol	
Look, M	2000	16	1215	AIDS Res Hum Retrovi	HCAPLUS
Look, M	1997	51	266	Eur J Clin Nutr	MEDLINE
Look, M	2000	35	866	Scand J Gastroentero	HCAPLUS
Martin, J	2001	285	1444	JAMA	MEDLINE
Mato, J	1999	30	1081	J Hepatol	HCAPLUS
Meister, A	1983	52	711	Annu Rev Biochem	HCAPLUS
Mudd, S	1995		1279	The Metabolic and Mo	
Muller, F	1996	63	242	Am J Clin Nutr	MEDLINE

Naurath, H	1995	346	85	Lancet	HCAPLUS
Nygard, O	1997	337	230	N Engl J Med	MEDLINE
Pace, G	1995	19	523	Free Radic Biol Med	HCAPLUS
Perry, I	1995	22	1395	Lancet	
Selhub, J	1992	55	131	Am J Clin Nutr	HCAPLUS
Selhub, J	1995	332	286	N Engl J Med	MEDLINE
Skurnick, J	1996	12	75	J Aquir Immune Defic	MEDLINE
Staal, F	1992	8	807	AIDS Res Hum Retrovi	
Stabler, S	1993	81	3404	Blood	MEDLINE
Stein, D	1997	175	1161	J Infect Dis	
Ubbink, J	1999	70	789	Am J Clin Nutr	HCAPLUS
Ubbink, J	1985	342	277	J Chromatogr	HCAPLUS
Ubbink, J	1996	98	177	J Clin Invest	HCAPLUS
van der Ven, A	1998	28	187	Eur J Clin Invest	MEDLINE

L37 ANSWER 28 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:838939 HCAPLUS
DN 136:144717
TI Interferon and ribavirin combination therapy for chronic **hepatitis C** in human immunodeficiency virus-infected patients with congenital coagulation disorders
AU Sauleda, Silvia; Juarez, Alberto; Esteban, Juan I.; Altisent, Carmen; Ruiz, Isabel; Puig, Lluis; Esteban, Rafael; Guardia, Jaime
CS Centre de Transfusio i Banc de Teixits, Servei Catala de la Salut, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain
SO Hepatology (Philadelphia, PA, United States) (**2001**), 34(5), 1035-1040
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
AB We have conducted an open, prospective trial to assess the safety and efficacy of interferon alfa-2b and ribavirin in combination for the treatment of chronic **hepatitis C** in human immunodeficiency virus (HIV)-infected hemophiliacs. Twenty hemophiliacs coinfected with HIV and **hepatitis C virus** (**HCV**), 18 of them under highly active antiretroviral therapy (HAART), with a mean CD4+ cell count of 490 ± 176 cells/mm3 and undetectable (n = 9) or low-level HIV RNA (<10,000 copies/mL; n = 11), were treated with interferon-alpha2b (3 MU thrice weekly) and ribavirin (800 mg/d) for 6 or 12 mo according to virol. response. Patients were monitored for tolerance and response at 4, 8, 12, 24, 36, and 48 wk during treatment and every other month thereafter. All 20 patients enrolled completed at least 6 mo of treatment with no major side effect requiring treatment withdrawal, dose reduction, or modification of HAART. Overall, 8 patients (40%) achieved a sustained virol. response at the end of the 6-mo post-treatment follow-up. Sustained responders had lower baseline **HCV**-RNA levels (5.7 ± 0.8 vs. 6.3 ± 0.4 log10 IU/mL, P = .041) but were otherwise similar to nonresponders. All sustained responders had a decrease in **HCV**-RNA level of at least 1 log per mo during the first 2 mo and undetectable levels at 6 mo. In conclusion, our results provide evidence that combination therapy with interferon and ribavirin is safe in HIV-infected hemophiliacs with stable CD4 cell count and undetectable or low-level HIV replication, and leads to eradication of **HCV** in 40% of these patients.
IT **3056-17-5**, Stavudine
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(interferon and ribavirin combination therapy for chronic

hepatitis C in HIV infected humans with congenital coagulation disorders)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Causse, X	2000	32	1003	J Hepatol	HCAPLUS
Darby, S	1997	350	1425	Lancet	MEDLINE
Davis, G	1998	339	1493	N Engl J Med	HCAPLUS
Dieterich, D	1999			50th AASLD Annua	
Dieterich, D	1999	107	79S	Am J Med	MEDLINE
Eyster, M	1993	6	602	J Acquir Immune Defi	MEDLINE
Greub, G	2000	356	1800	Lancet	MEDLINE
John, M	1998	12	2289	AIDS	HCAPLUS
Landau, A	2000	14	1857	AIDS	HCAPLUS
Landau, A	2000	14	839	AIDS	HCAPLUS
Lessens, O	1999	79	1254	J Infect Dis	
Makris, M	1996	94	746	Br J Haematol	MEDLINE
Martin, P	1989	97	1559	Gastroenterology	MEDLINE
McHutchinson, J	2000			51st AASLD Annua	
McHutchison, J	1998	339	1485	N Engl J Med	HCAPLUS
Morsica, G	2000	14	1656	AIDS	HCAPLUS
Puoti, M	2000	181	2033	J Infect Dis	MEDLINE
Rockstroh, J	1996	91	2563	Am J Gastroenterol	MEDLINE
Sauleda, S	2000	83	807	Thromb Haemost	HCAPLUS
Sim, S	1998	14	1661	AIDS Res Hum Retrovi	HCAPLUS
Soriano, V	1996	23	585	Clin Infect Dis	HCAPLUS
Sulkowski, M	2000	283	74	JAMA	HCAPLUS
Tedder, R	1991	79	512	Br J Haematol	MEDLINE
Telfer, P	1994	87	555	Br J Haematol	MEDLINE
Troisi, C	1993	81	1412	Blood	
Vogt, M	1987	235	1376	Science	HCAPLUS
Zybelberg, H	1998	27	1255	Clin Infect Dis	
Zylberberg, H	2000	47	694	Gut	HCAPLUS

L37 ANSWER 29 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN **2001:808478** HCAPLUS
DN 136:114686
TI **Hepatitis C Virus** NS3 NTPase/Helicase: Different Stereoselectivity in Nucleoside Triphosphate Utilisation Suggests that NTPase and Helicase Activities are Coupled by a Nucleotide-dependent Rate Limiting Step
AU Locatelli, Giada A.; Gosselin, Gilles; Spadari, Silvio; Maga, Giovanni
CS Istituto di Genetica Biochimica ed Evoluzionistica IGBE-CNR, Pavia, Italy

SO Journal of Molecular Biology (**2001**), 313(4), 683-694
CODEN: JMOBAK; ISSN: 0022-2836
PB Academic Press
DT Journal
LA English

AB **Hepatitis C virus** (**HCV**) NS3 protein is a multifunctional enzyme, possessing protease, NTPase and helicase activities within a single polypeptide of 625 amino acid residues. These activities are essential for the virus life cycle and are considered attractive targets for anti-**HCV** chemotherapy. Beside ATP, the NS3 protein has the ability to utilize deoxynucleoside triphosphates (dNTPs) as the energy source for nucleic acid unwinding. We have performed an extensive anal. of the substrate specificities of both NS3 NTPase and helicase activities with respect to all four dNTPs as well as with dideoxynucleoside triphosphate (ddNTP) analogs, including both D-(β) and L-(β)-deoxy and dideoxy-nucleoside triphosphates. Our results show that almost all dNTPs and ddNTPs tested were able to inhibit hydrolysis of ATP by the NTPase activity, albeit with different efficiencies. Moreover, this activity showed almost no stereoselectivity, being able to recognize both D-(β), L-(β)-deoxy and ddNTPs. On the contrary, the helicase activity had more strict substrate selectivity, since, among D-(β)-nucleotides, only ddTTP and its analog 2',3'-didehydro-thymidine triphosphate could be used as substrates with an efficiency comparable to ATP, whereas among L-(β)-nucleotides, only L-(β)-dATP was utilized. Comparison of the steady-state kinetic parameters for both reactions, suggested that dATP, L-(β)-dCTP and L-(β)-dTTP, specifically reduced a rate limiting step present in the helicase, but not in the NTPase, reaction pathway. These results suggest that NS3-associated NTPase and helicase activities have different sensitivities towards different classes of deoxy and dideoxy-nucleoside analogs, depending on a specific step in the reaction, as well as show different enantioselectivity for the D-(β) and L-(β)-conformations of the sugar ring. These observations provide an essential mechanistic background for the development of specific nucleotide analogs targeting either activity as potential anti-**HCV** agents. (c) 2001 Academic Press.

IT **611-60-9**, DdTTP **26194-89-8**, 2',3'-Didehydro-3'-deoxythymidine 5'-triphosphate **66004-77-1**, DdCTP **161170-30-5**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stereoselectivity of **hepatitis C virus** NS3 NTPase/helicase suggests NTPase and helicase activities are coupled by nucleotide-dependent rate limiting step)

RN 611-60-9 HCAPLUS
CN Thymidine 5'-(tetrahydrogen triphosphate), 3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26194-89-8 HCAPLUS
CN Thymidine 5'-(tetrahydrogen triphosphate), 2',3'-didehydro-3'-deoxy- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 66004-77-1 HCAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161170-30-5 HCAPLUS
CN Triphosphoric acid, P-[[(2R,5S)-5-(4-amino-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bartenschlager, R	1995	69	7519	J Virol	HCAPLUS
Borowski, P	2001	75	3220	J Virol	HCAPLUS
Bujalowski, W	2000	39	2106	Biochemistry	HCAPLUS
Butkiewicz, N	1996	225	328	Virology	HCAPLUS
Choo, Q	1991	88	2451	Proc Natl Acad Sci U	HCAPLUS
Choo, Q	1989	244	359	Science	HCAPLUS
Clarke, B	1997	78	2397	J Gen Virol	HCAPLUS
Gallinari, P	1998	72	6758	J Virol	HCAPLUS
Gorbalenya, A	1993	3	419	Curr Opin Struct Bio	HCAPLUS
Gwack, Y	1996	225	654	Biochem Biophys Res	HCAPLUS
Gwack, Y	1997	250	47	Eur J Biochem	HCAPLUS

Jin, L	1995	323	47	Arch Biochem Biophys	HCAPLUS
Kim, J	1998	6	89	Structure	HCAPLUS
Kwong, A	1999	41	67	Antiviral Res	MEDLINE
Kwong, A	2000	242	171	Curr Top Microbiol I	HCAPLUS
Levin, M	1999	274	31839	J Biol Chem	HCAPLUS
Lin, C	1999	73	8798	J Virol	HCAPLUS
Lohman, T	1996	65	169	Annu Rev Biochem	HCAPLUS
Maga, G	1994	302	279	Biochem J	HCAPLUS
Maga, G	1999	27	972	Nucl Acids Res	HCAPLUS
Maga, G	1999	18	795	Nucleos Nucleot	HCAPLUS
Marians, K	2000	8	R227	Struct Fold Des	HCAPLUS
Markland, W	1997	78	39	J Gen Virol	HCAPLUS
Paolini, C	2000	81	1335	J Gen Virol	HCAPLUS
Patel, S	2000	69	651	Annu Rev Biochem	HCAPLUS
Preugschat, F	1996	271	24449	J Biol Chem	HCAPLUS
Rajendran, S	2000	303	773	J Mol Biol	HCAPLUS
Spadari, S	1995	77	861	Biochimie	HCAPLUS
Spadari, S	1995	47	1231	Mol Pharmacol	HCAPLUS
Tackett, A	2001	29	565	Nucl Acids Res	HCAPLUS
Tai, C	1996	70	8477	J Virol	HCAPLUS
Utama, A	2000	273	316	Virology	HCAPLUS
Walker, M	1999	4	518	Drug Discov Today	HCAPLUS
Wardell, A	1999	80	701	J Gen Virol	HCAPLUS
Yan, Y	1998	7	837	Protein Sci	HCAPLUS
Yao, N	1999	7	1353	Struct Fold Des	HCAPLUS
Yong, Y	1995	270	24509	J Biol Chem	HCAPLUS

L37 ANSWER 30 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:784185 HCAPLUS
DN 136:95621
TI Low frequency of severe hepatotoxicity and association with **HCV** coinfection in HIV-positive patients treated with HAART
AU Monforte, Antonell d'Arminio; Bugarini, Roberto; Pezzotti, Patrizio; De Luca, Andrea; Antinori, Andrea; Mussini, Cristina; Vigevani, Gian Marco; Tirelli, Umberto; Bruno, Raffaele; Gritti, Francesco; Piazza, Marcello; Chigiotti, Silvia; Chirianni, Antonio; De Stefano, Carlo; Pizzigallo, Eligio; Perrella, Oreste; Moroni, Mauro
CS ICONA Study Group, Institute of Infectious and Tropical Diseases, L Sacco H, University of Milan, Milan, 20157, Italy
SO JAIDS, Journal of Acquired Immune Deficiency Syndromes (**2001**), 28(2), 114-123
CODEN: JJASFJ
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Highly active antiretroviral therapy (HAART) is strongly effective in reducing morbidity and mortality in HIV-1-pos. individuals. Its main drawback is the potential toxicity. Data on the frequency and determinants of severe hepatotoxicity in a clin. setting are still sparse. This is a prospective study of HIV-1-pos. individuals with known HBsAg and **HCV**-Ab serol. The study end point was progression to alanine aminotransferase (ALT) levels ≥200 IU/L after HAART initiation. Cumulative probability of progression to this end point was estimated by the Kaplan-Meier method. Crude and adjusted hazard ratios (HR) were estimated by proportional hazards regression model. One thousand two hundred fifty-five patients were included. HBsAg was found in 91 (7.2%), **HCV**-Ab in 578 (46.5%) patients; almost all injection drug users (451 of 482; 93.6%) were **HCV**-Ab pos. Sixty-one individuals progressed to the end point with a probability of 7.9% (95% confidence interval [CI], 5.6-10.0) of progression at 24 mo from starting.

Independent factors predicting progression to the end point were baseline ALT levels (HR, 5.29; 95% CI, 3.24-8.65; every 10 IU/L higher), **HCV**-Ab positivity (HR, 4.01; 95% CI, 1.48-10.85) or both HBsAg and **HCV**-Ab positivity (HR, 3.85, 95% CI, 1.01-14.61), and previous non-HAART therapy (HR, 1.84, 95% CI, 1.04-3.42). Patients receiving stavudine-containing regimens had a lower risk than those receiving zidovudine-containing regimens (HR, 0.30, 95% CI, 0.12-0.71). There was a low risk of ALT ≥200 IU/L in the authors' cohort. **Hepatitis C** coinfection and elevated ALT levels at HAART initiation are important predictors of progression to ALT ≥200 IU/L; stavudine-containing regimens were associated with a lower risk compared with zidovudine-containing regimens.

IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: ADV (Adverse effect, including toxicity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(low frequency of severe hepatotoxicity and association with **HCV** coinfection in HIV-pos. humans treated with HAART)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	2000	1	76	HIV Medicine	
Arribas, J	1998	12	1722	AIDS	MEDLINE
Carpenter, C	2000	283	381	JAMA	MEDLINE
Carr, A	1998	12	F51	AIDS	MEDLINE
Carr, A	1999	353	2093	Lancet	MEDLINE
Centers for Disease Con	1992	41	19	MMWR Morb Mortal Wkl	
den Brinker, M	2000	14	2895	AIDS	HCAPLUS
Garfein, R	1996	86	655	Am J Pub Health	MEDLINE
Giusti, G	1989	17	237	Infection	MEDLINE

John, M	1998	12	2289	AIDS	HCAPLUS
Lee, B	1992	14	773	Clin Infect Dis	MEDLINE
Liang, K	1986	73	13	Biometrika	
Mele, A	1996	VII	1	Rapporti ISTISAN 96/	
Mocroft, A	1998	352	1725	Lancet	MEDLINE
Monforte d'A	2000	14	499	AIDS	
Palella, F	1998	338	853	N Engl J Med	
Perrillo, R	1986	105	3382	Ann Intern Med	
Rodriguez-Rosado, R	1998	12	1256	AIDS	MEDLINE
Rutschmann, O	1998	177	783	J Infect Dis	HCAPLUS
Sulkowski, M	2000	283	74	JAMA	HCAPLUS
Thomas, D	1998	28	568	Hepatology	
Vanhove, G	1996	276	1955	JAMA	MEDLINE
Vento, S	1998	12	116	AIDS	MEDLINE
Zylberberg, H	1998	26	1104	Clin Infect Dis	MEDLINE

L37 ANSWER 31 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:682395 HCAPLUS
DN 135:366359
TI Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy
AU Nunez, Marina; Lana, Raquel; Mendoza, Juan Luis; Martin-Carbonero, Luz; Soriano, Vincent
CS Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
SO JAIDS, Journal of Acquired Immune Deficiency Syndromes (**2001**), 27(5), 426-431
CODEN: JJASFJ
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Treatment of HIV infection with highly antiretroviral therapy (HAART) may be limited by liver toxicity. Its incidence and risk factors are not well known. Retrospective chart review. Naive patients beginning HAART between Jan. 1997 and Jan. 2000. Severe transaminase elevation was defined as fivefold or higher rise over upper normal limits, or as ≥3.5-fold rise above abnormal baseline values. Of 222 study subjects, 38%, 5%, and 2% were coinfected with **hepatitis C virus** (**HCV**), **hepatitis** B virus, and **hepatitis** D virus, resp. Besides two nucleoside reverse transcriptase inhibitors (NRTIs), 96 patients received protease inhibitors (PIs), 90 received nonnucleoside reverse transcriptase inhibitors (NNRTIs), and 35 received a PI + NNRTI combination. Severe hepatic injury developed in 21 (9%): 10% PI, 9%, and 9% PI + NNRTI. Both univariate and multivariate analyses identified alc. abuse, **HCV** coinfection, and older age as independent risk factors. Predictor variables in the final multivariate model were: alc. abuse (risk ratio [RR], 5.87; 95% confidence interval [CI], 1.49-23.15: p = .01), pos. **HCV** serol. (RR. 3.99; 95% CI, 1.32-12.10; p = .01), and older age (RR, 1.11; 95% CI, 1.04-1.18; p = 0.001). Nearly 10% of study subjects who start HAART experience severe transaminase elevation, irresp. of the treatment. Avoidance of alc. abuse, especially in study subjects coinfected with **HCV**, will reduce the risk of hepatic injury after HAART. When possible, prior treatment for chronic **HCV** infection should be considered.
IT **3056-17-5**, Stavudine
RL: ADV (Adverse effect, including toxicity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(highly active antiretroviral therapy and risk factors for severe hepatic injury in HIV-infected humans)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aids Clinical Trials Gr	1996			Table of grading sev	
Alonso, M	2000	115	481	Med Clin (Barc)	
Barreiro, P	2000	14	807	AIDS	HCAPLUS
Benhamou, Y	1996	125	705	Ann Intern Med	HCAPLUS
Brau, N	1997	349	924	Lancet	MEDLINE
Cahn, P	2000			[abstract PL8.6] 5th	
Den Brinker, M	2000	14	2895	AIDS	HCAPLUS
Fortgang, I	1995	90	1433	Am J Gastroenterol	MEDLINE
Freiman, J	1993	7	379	AIDS	MEDLINE
Gavazzi, G	2000	16	1021	AIDS Res Hum Retrovi	HCAPLUS
John, M	1998	12	2289	AIDS	HCAPLUS
Kew, L	1991	115	283	Ann Intern Med	
Landau, A	2000	14	839	AIDS	HCAPLUS
Martinez, E	2000			(abstract PL8.5) 5th	
Morsica, G	2000	14	1656	AIDS	HCAPLUS
Moyle, G	1999	8	473	Exp Opin Invest Drug	HCAPLUS
Murphy, R	1996	5	1183	Exp Opin Invest Drug	HCAPLUS
Perez-Olmeda, M	1999	22	308	J Acquir Immune Defi	HCAPLUS
Pezzotti, P	2000			[abstract TuPpB1161]	
Piroth, L	2000	34	534	Ann Pharmacother	MEDLINE
Rodriguez-Rosado, R	1998	12	1256	AIDS	MEDLINE
Sanne, I	2000			[abstract PL9.3] 5th	
Sauleda, S	2000		A751	Hepatology	
Saves, M	1999	13	F115	AIDS	HCAPLUS
Saves, M	2000	44	3451	Antimicrob Agents Ch	HCAPLUS
Sulkowski, M	2000	283	74	JAMA	HCAPLUS
Torriani, F	2000	2	168	AIDS Rev	

L37 ANSWER 32 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:617821 HCAPLUS
DN 135:175348
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating **hepatitis** virus infections
IN Mueller, Richard A.; Bryant, Martin L.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060366	A1	20010823	WO 2001-US4512	20010213 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001036938	A5	20010827	AU 2001-36938	20010213 <--
	EP 1261339	A1	20021204	EP 2001-909153	20010213 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003522791	T2	20030729	JP 2001-559463	20010213 <--
	US 2005119310	A1	20050602	US 2002-203769	20010213 <--
PRAI	US 2000-182362P	P	20000214 <--		
	WO 2001-US4512	W	20010213 <--		

AB Provided are methods and compns. for treating **hepatitis** virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixts. thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixts. thereof, and immunomodulating/immuno stimulating agents.

IT **3056-17-5**, Stavudine **7481-89-2**, Dideoxycytidine **121154-51-6 147058-39-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **hepatitis** B and C virus infections with dideoxyiminoglucitols and antiviral nucleosides and nucleotides)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 121154-51-6 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 147058-39-7 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Block, T	1998	4	610	NATURE MEDICINE	HCAPLUS
Block, T	1994	91	2235	PROCEEDINGS OF THE N	HCAPLUS
Dwek, R	1998			WO 9835685 A	HCAPLUS
Mueller, R	1999			WO 9940916 A	HCAPLUS
Mueller, R	2000			WO 0047198 A	HCAPLUS
Platt, F	1994		106	CHEMTRACTS ORGANIC C	
Searle & Co	1995			WO 9519172 A	HCAPLUS
Zitzmann, N	1999			WO 9929321 A	HCAPLUS
Zitzmann, N	1999	96	11878	PROCEEDINGS OF THE N	HCAPLUS

L37 ANSWER 33 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:617773 HCAPLUS
DN 135:175346
TI Method for the treatment or prevention of flavivirus infections using

nucleoside analogues
IN Ismaili, Hicham Moulay Alaoui; Cheng, Yun-Xing; Lavallee, Jean-Francois; Siddiqui, Arshad; Storer, Richard
PA Biochem Pharma Inc., Can.
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060315	A2	20010823	WO 2001-CA197	20010219 <--
	WO 2001060315	A3	20030116		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2400274	AA	20010823	CA 2001-2400274	20010219 <--
	AU 2001035278	A5	20010827	AU 2001-35278	20010219 <--
	EP 1296690	A2	20030402	EP 2001-907276	20010219 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003523978	T2	20030812	JP 2001-559414	20010219 <--
	NZ 521210	A	20041126	NZ 2001-521210	20010219 <--
	~~US 20020193363~~	A1	20020214	US 2001-785235	20010220 <--
	~~US 6784161~~	B2	20040831		
	ZA 2002006506	A	20031114	ZA 2002-6506	20020814 <--
	NO 2002003884	A	20021017	NO 2002-3884	20020816 <--
	US 2004248844	A1	20041209	US 2004-887292	20040709 <--
PRAI	US 2000-183349P	P	20000218 <--		
	WO 2001-CA197	W	20010219 <--		
	US 2001-785235	A1	20010220 <--		

OS MARPAT 135:175346
AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogs in a host comprising administering a therapeutically effective amount of the nucleoside analog or a pharmaceutically acceptable salt thereof.
IT **611-60-9**, 3'-Deoxythymidine-5'-triphosphate **3416-05-5**, 3'-Deoxythymidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to **hepatitis C virus RNA-dependent RNA polymerase** (NS5B protein))
RN 611-60-9 HCAPLUS
CN Thymidine 5'-(tetrahydrogen triphosphate), 3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3416-05-5 HCAPLUS
CN Thymidine, 3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **9026-28-2, RNA-dependent RNA polymerase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to **hepatitis C virus RNA-dependent RNA polymerase** (NS5B protein))
RN 9026-28-2 HCAPLUS
CN Nucleotidyltransferase, ribonucleate, RNA-dependent (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L37 ANSWER 34 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:166174 HCAPLUS
DN 134:347992
TI **Hepatitis** B or **hepatitis C virus** infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
AU Saves, Marianne; Raffi, Francois; Clevenbergh, Philippe; Marchou, Bruno; Waldner-Combernoux, Anne; Morlat, Philippe; Le Moing, Vincent; Riviere, Catherine; Chene, Genevieve; Leport, Catherine; Leport, C.; Raffi, F.; Chene, G.; Salamon, R.; Moatti, J.-P.; Pierret, J.; Brun-Vezinet, F.; Fleury, H.; Peytavin, G.; Costagliola, D.; Dellamonica, P.; Katlama, C.; Meyer, L.; Morin, M.; Sicard, D.; Sobel, A.; Vincent-Ballereau, F.; Dupon, M.; Le Moing, V.; Marchou, B.; May, T.; Morlat, P.; Waldner-Combernoux, A.; Agid, F.; Bourdillon, F.; Delfraissy, J.-F.; Dormont, J.; Lacut, J.-Y.; Souteyrand, Y.; Vilde, J.-L.; Cailleton, V.; Carricaburu, D.; Deveaud, C.; Dupouy, G.; Dutoit, S.; Ecobichon, J.-L.; Egouy, C.; Jadand, C.; Joly, P.; Journot, V.; Lawson-Ayayi, S.; Lewden, C.; Masquelier, B.; Nouioua, W.; Palmer, G.; Saves, M.; Souville, M.; Chauvin, J. P.; Delavelle, D.; Dohin, E.; Gallet, B.; Gervais, M.-C.; Lapierre, D.; Schmit, J. L.; Chennebault, J.-M.; Faller, J.-P.; Estavoyer, J.-M.;

Laurent, R.; Vuitton, D.; Beylot, J.; Lacut, J.-Y.; Le Bras, M.; Ragnaud, J.-M.; Granier, P.; Garre, M.; Bazin, C.; Veyssier, P.; Devidas, A.; Sobel, A.; Portier, H.; Perronne, C.; Lagarde, P.; Ceccaldi, J.; Peyramond, D.; Allard, C.; Reynes, J.; Canton, P.; Raffi, F.; Cassuto, J.-P.; Dellamonica, P.; Arsac, P.; Bricaire, F.; Caulin, C.; Frottier, J.; Herson, S.; Imbert, J.-C.; Malkin, J.-E.; Rozenbaum, W.; Sicard, D.; Vachon, F.; Vilde, J.-L.; Becq-Giraudon, B.; Remy, G.; Cartier, F.; Lucht, F.; Roue, R.; Lang, J.-M.; Jaubert, D.; Massip, P.; Choutet, P.

CS INSERM Unite 330, Bordeaux, 33076, Fr.

SO Antimicrobial Agents and Chemotherapy (**2000**), 44(12), 3451-3455
CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

AB In a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors (PIs), the incidence of severe hepatic cytolysis (alanine aminotransferase concentration five times or more above the upper limit of the normal level ≥ 5N) was 5% patient-years after a mean follow-up of 5 mo. Only positivity for **hepatitis C virus** antibodies (hazard ratio [HR], 7.95; P < 10-3) or **hepatitis** B virus surface antigen (HR, 6.67; P < 10-3) was associated with severe cytolysis. Before starting patients on PIs, assessment of liver enzyme levels and viral coinfections is necessary.

IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**hepatitis** B or C virus infection as risk for severe hepatic cytolysis after initiation of protease inhibitor-containing antiretroviral regimen in HIV infection)

RN 3056-17-5 HCAPLUS

CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS

CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Arribas, J	1998	12	1722	AIDS	MEDLINE
Brau, N	1997	349	924	Lancet	MEDLINE
Cameron, D	1998	351	543	Lancet	HCAPLUS
Carr, A	1997	349	995	Lancet	MEDLINE
Collier, A	1996	334	1011	N Engl J Med	HCAPLUS
Division of AIDS, Natio	1996			Division of AIDS tab	
Gulick, R	1997	337	734	N Engl J Med	HCAPLUS
Hammer, S	1997	337	725	N Engl J Med	HCAPLUS
Havlir, D	1998	339	1261	N Engl J Med	HCAPLUS
Jeurissen, F	1998	12	441	AIDS	MEDLINE
John, M	1998	12	2289	AIDS	HCAPLUS
Karch, F	1977	21	247	Clin Pharmacol Ther	MEDLINE
Matsuda, J	1997	350	364	Lancet	MEDLINE
Nelson, D	1997	158	1473	J Immunol	HCAPLUS
Pialoux, G	1998	339	1269	N Engl J Med	HCAPLUS
Rutschmann, O	1998	177	783	J Infect Dis	HCAPLUS
USPHS/IDSA Prevention o	2000	30	S29	Clin Infect Dis	
Vento, S	1998	12	116	AIDS	MEDLINE
Vergis, E	1998	9	53	Int J Sex Transm Dis	MEDLINE
Zylberberg, H	1998	26	1104	Clin Infect Dis	MEDLINE
Zylberberg, H	1998	27	1255	Clin Infect Dis	MEDLINE

L37 ANSWER 35 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:100967 HCAPLUS
DN 134:141721
TI N-Substituted glucamine compounds for treating **hepatitis** virus infections
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362785	AA	20010208	CA 2000-2362785	20000214 <--
	EP 1173161	A2	20020123	EP 2000-917640	20000214 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6515028	B1	20030204	US 2000-503865	20000214 <--
	JP 2003505501	T2	20030212	JP 2001-513402	20000214 <--
	US 2003195229	A1	20031016	US 2002-322045	20021217 <--
	US 6747149	B2	20040608		
PRAI	US 1999-119836P	P	19990212 <--		
	US 1999-119858P	P	19990212 <--		

US 2000-503865 A1 20000214 <--
WO 2000-US3816 W 20000214 <--
OS MARPAT 134:141721
AB N-Substituted glucamine compds. (Markush included) are effective in treatment of **hepatitis** infections, including **hepatitis** B and **hepatitis C.** In treating **hepatitis** infections, the compds. of the invention may be used alone or in combination with another antiviral agent selected from nucleosides, nucleotides, immunomodulators, immunostimulants, or various combinations of such other agents. Preparation of e.g. 1,5-(butylimino)-1,5-dideoxy-D-glucitol tetraacetate is described.
IT **3056-17-5**, Stavudine **7481-89-2**, Dideoxycytidine **147058-39-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(N-substituted glucamine compds. for treating **hepatitis** virus infections, and use with other agents)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 147058-39-7 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L37 ANSWER 36 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:90894 HCAPLUS
DN 135:313173
TI Increased mitochondrial toxicity with ribavirin in HIV/**HCV** coinfection
AU Lafeuillade, A.; Hittinger, G.; Chadapaud, S.
CS Department of Infectious Diseases, Hospital Chalucet, Toulon, 83056, Fr.
SO Lancet (**2001**), 357(9252), 280-281
CODEN: LANCAO; ISSN: 0140-6736
PB Lancet Ltd.
DT Journal
LA English
AB In two of 15 patients coinfected with HIV and **hepatitis C virus** who received interferon-α plus ribavirin in addition to HAART, we observed multiorgan dysfunction and lactic acidemia. As ribavirin is a nucleoside analog, an increased risk of mitochondrial toxicity can be induced in HIV-infected patients already treated with nucleoside analogs, leading to clin. deterioration in some cases.
IT **3056-17-5**, Stavudine
RL: ADV (Adverse effect, including toxicity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(increased mitochondrial toxicity with ribavirin in HIV/**HCV** coinfection)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Brinkman, K	1999	354	1112	Lancet	HCAPLUS
Carr, A	2000	14	F25	AIDS	HCAPLUS
Kochhar, D	1980	52	99	Toxicol Appl Pharmac	HCAPLUS
McKenzie, R	1995	333	1099	N Engl J Med	HCAPLUS

Weiss, R |1993 |16 |301 |J Vet Pharmacol Ther|HCAPLUS

L37 ANSWER 37 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:60217 HCAPLUS
DN 135:116588
TI **Hepatitis** B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
AU den Brinker, Marieke; Wit, Ferdinand W. N. M.; Wertheim-van Dillen, Pauline M. E.; Jurriaans, Suzanne; Weel, Jan; van Leeuwen, Remko; Pakker, Nadine G.; Reiss, Peter; Danner, Sven A.; Weverling, Gerrit Jan; Lange, Joep M. A.
CS Department of Internal Medicine, National AIDS Therapy Evaluation Center (NATEC), Amsterdam, 1105 AZ, Neth.
SO AIDS (London) (**2000**), 14(18), 2895-2898
CODEN: AIDSET; ISSN: 0269-9370
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB The objective was to investigate the risk of hepatotoxicity after initiation of protease inhibitor-containing highly active antiretroviral therapy (HAART) for HIV-1 infected patients with chronic **hepatitis** B virus (HBV) or **hepatitis C virus** (**HCV**) co-infection. Design: Retrospective study with 394 HIV-1-infected patients initiating HAART at a single university clinic. Methods: Liver enzyme elevation (LEE) was defined as alanine aminotransferase or aspartate aminotransferase at least five times the upper limit of normal and an absolute increase of > 100 U/l. Relative risks for time to LEE were estimated using Cox proportional hazards models. Results: Of 394 patients 7% were **hepatitis** B surface antigen (HBsAg)-pos. and 14% were anti-**HCV**-pos. Patients with chronic **hepatitis** had a higher risk for LEE compared with patients without co-infection: 37% vs. 12% resp. After adjustment for higher baseline transaminases, the presence of HBsAg or anti-**HCV** remained associated with an increased risk of LEE - relative risk 2.78 (95% confidence interval, 1.50-5.16) and 2.46 (95% confidence interval, 1.43-4.24) resp. In patients with LEE, transaminases declined whether HAART was continued or modified. Of patients with chronic HBV infection 38% lost HBeAg or developed anti-HBe after initiation of HAART, and one seroconverted from HBsAg-pos. to anti-HBs-pos. However, there was no clear relationship with LEE. Conclusions: HIV-1-infected patients co-infected with HBV or **HCV** were at considerably higher risk of developing LEE when HAART was initiated compared with patients without co-infection, but it is usually not necessary to modify antiretroviral therapy.
IT **3056-17-5**, Stavudine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**hepatitis** B and C virus co-infection and risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infected human patients)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L37 ANSWER 38 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN **2000:867640** HCAPLUS
DN 135:40476
TI The **hepatitis C virus** NS5B **RNA-dependent RNA polymerase** activity and susceptibility to inhibitors is modulated by metal cations
AU Alaoui-Ismaili, Moulay Hicham; Hamel, Martine; L'Heureux, Lucille; Nicolas, Olivier; Bilimoria, Darius; Labonte, Patrick; Mounir, Samir; Rando, Robert F.
CS BioChem Pharma Inc., Laval, QC, H7V 4A7, Can.
SO Journal of Human Virology (**2000**), 3(6), 306-316
CODEN: JHVIFC; ISSN: 1090-9508
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Objectives: The aim of this study was to understand the effect of metal cations on the **hepatitis C virus** (**HCV**) NS5B in vitro **RNA-dependent RNA polymerase** (RdRp) activity and its susceptibility to various inhibitors. Methods: A recombinant full-length **HCV** NS5B protein was expressed in insect cells and purified to homogeneity. RdRp activity was assessed using standard filtration or polyacrylamide gel-based assays. Results: Efficient inhibition of the **HCV** NS5B RdRp activity by gliotoxin, as well as by various substrate analogs, occurs in the presence of Mn2+, but not of Mg2+. Assays performed in the presence of both cofactors suggest that, in vitro, the enzyme's affinity for Mn2+ is higher than that for Mg2+. In addition, the RdRp activity, displayed in the presence of heteropolymeric templates, is significantly increased when the metal cofactor consists of Mn2+. Finally, steady state kinetics showed that the velocity of the reaction, as well as the affinity of the enzyme for its substrate, could both be affected by the nature of the divalent metal cation used.
IT **9026-28-2**, **RNA-dependent RNA polymerase**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NS5B; **hepatitis C virus** NS5B **RNA-dependent RNA polymerase** activity and susceptibility to inhibitors is modulated by metal cations in vitro)
RN 9026-28-2 HCAPLUS
CN Nucleotidyltransferase, ribonucleate, RNA-dependent (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **66004-77-1**, 2'-3' Dideoxycytidine triphosphate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(**hepatitis C virus** NS5B **RNA-dependent RNA polymerase** activity and susceptibility to inhibitors is modulated by metal cations in vitro)

RN 66004-77-1 HCAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Al, R	1998	53	141	Virus Res	HCAPLUS
Beese, L	1991	10	25	EMBO J	HCAPLUS
Behrens, S	1996	15	12	EMBO J	HCAPLUS
Bressanelli, S	1999	96	13034	Proc Natl Acad Sci	HCAPLUS
Choo, Q	1989	244	359	Science	HCAPLUS
Clarke, B	1997	78	2397	J Gen Virol	HCAPLUS
Ferrari, E	1999	73	1649	J Virol	HCAPLUS
Harlow, E	1998			Antibodies: a labora	
Hideo, A	1999	7	1417	Structure	
Ishii, K	1999	29	1227	Hepatology	HCAPLUS
Johnson, R	2000	377	129	Arch Biochem Biophys	HCAPLUS
Joyce, M	1997	94	1619	Proc Natl Acad Sci	
Koonin, E	1991	72	2197	J Gen Virol	
Lesburg, C	1999	10	937	Nat Struct Biol	
Lohmann, V	1997	71	8416	J Virol	HCAPLUS
Lohmann, V	1998	249	108	Virology	HCAPLUS
Luo, G	2000	74	851	J Virol	HCAPLUS
Miller, P	1969	159	431	Science	
Murphy, F	1995		424	Sixth report of the	
Oh, J	1999	73	7694	J Virol	HCAPLUS
O'Reilly, E	1998	252	287	Virology	HCAPLUS
Rodriguez, P	1992	66	1971	J Virol	HCAPLUS
Saito, I	1990	87	6547	Proc Natl Acad Sci	HCAPLUS
Steitz, T	1998	391	231	Nature	HCAPLUS
Sun, X	2000	268	798	Biochem Biophys Res	HCAPLUS
Tabor, S	1989	86	4076	Proc Natl Acad Sci	HCAPLUS
Tomei, L	2000	81	759	J Gen Virol	HCAPLUS
Tomei, L	1993	67	4017	J Virol	HCAPLUS
Trown, P	1972	2	261	Antimicrob Agents Ch	HCAPLUS
Yamashita, T	1998	273	15479	J Biol Chem	HCAPLUS
Yuan, Z	1997	232	231	Biochem Biophys Res	HCAPLUS
Zhong, W	2000	74	2017	J Virol	HCAPLUS

L37 ANSWER 39 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:840382 HCAPLUS

DN 135:40464

TI Safety and efficacy of interferon-ribavirin combination therapy in **HCV**-HIV coinfected subjects: An early report

AU Zylberberg, H.; Benhamou, Y.; Lagneaux, J. L.; Landau, A.; Chaix, M. -L.; Fontaine, H.; Bochet, M.; Poynard, T.; Katlama, C.; Pialoux, G.; Brechot, C.; Pol, S.

CS Unite d'Hepatologie, INSERM U370, Unite d'Hepatologie, INSERM U370, CHU Necker, Paris, Fr.

SO Gut (**2000**), 47(5), 694-697
CODEN: GUTTAK; ISSN: 0017-5749

PB BMJ Publishing Group

DT Journal

LA English

AB More severe liver disease together with a poor response rate to α interferon argue for the use of more potent anti-**hepatitis C virus** (**HCV**) therapies in human immunodeficiency virus (HIV)-**HCV** coinfected patients, but the efficacy and safety of interferon-ribavirin combination therapy in HIV infected subjects are unknown. Aim of this study was to retrospectively evaluate the efficacy and safety of anti-**HCV** combination therapy in 21 **HCV**-HIV coinfected patients receiving antiretroviral therapy, and to access the clin. relevance of in vitro inhibition of phosphorylation by ribavirin of potent inhibitors of HIV-i.e., zidovudine, stavudine, and zalcitabine. Twenty one patients were treated with combined antiretroviral therapy including zidovudine (n=8) or stavudine (n=13) (in association with protease inhibitors in 12). All received ribavirin (1000 or 1200 mg/day) and α interferon (3 MU three times/wk) for chronic **hepatitis C** infection. All patients had not responded (n=20) or relapsed (n=1) after a previous six month course of α interferon therapy. HIV viral load (Monitor test) and CD4 cells count were measured at the beginning and every three months during and after ribavirin plus α interferon therapy over a mean period of 11 (1) months. Clin. and biol. adverse effects were recorded. There was no significant variation in HIV viral load or CD4 cell counts after three or six months of ribavirin therapy compared with baseline values. Of the 21 subjects, three (14%) had an increase in HIV viral load of more than 0.5 log leading to discontinuation of ribavirin in one. Eleven of 21 (52.4%) and initial neg. **HCV** viremia at three (n=10) or six (n=1) months but only six were **polymerase** chain reaction neg. at the end of therapy, leading to rates for primary response and breakthrough of 23.8% and 28.5%, resp. Six months after completion of therapy, three patients relapsed (14.3%) and three (14.3%) had sustained virol. response. Median Hb concentration decreased significantly after three and six months of ribavirin therapy (p=0.0002 and p=0.0003, resp.) leading to withdrawal of therapy in one patient. These preliminary results show that: (1) despite in vitro interactions between ribavirin, zidovudine, and stavudine, significant variation in HIV replication does not usually occur in **HCV**-HIV coinfected patients receiving ribavirin and different antiretroviral regimens, including zidovudine and stavudine; (2) α interferon and ribavirin combination therapy induced primary and sustained virol. responses in 28.5% and 14.3% of treated subjects (who were previous non-responders to interferon therapy), resp.; (3) anemia is a frequent adverse event. Such results should be confirmed in larger prospective trials.

IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(interferon-α and ribavirin combination therapy in humans coinfected with **hepatitis C virus** and HIV)

RN 3056-17-5 HCAPLUS

CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Baba, M	1987	31	1613	Antimicrob Agents Ch	HCAPLUS
Darby, S	1997	350	1425	Lancet	MEDLINE
Davis, G	1998	339	1493	N Engl J Med	HCAPLUS
Hoggard, P	1997	41	1231	Antimicrob Agents Ch	HCAPLUS
Mc Hutchinson, J	1998	339	1485	N Engl J Med	
Pol, S	1998	28	945	J Hepatol	HCAPLUS
Pol, S	1999	31	1	J Hepatol	HCAPLUS
Poynard, T	1998	352	1426	Lancet	HCAPLUS
Reichard, O	1998	351	83	Lancet	HCAPLUS
Roberts, R	1990	4	67	AIDS	MEDLINE
Spanish Ribavirin Trial	1991	338	6	Lancet	
Vogt, M	1987	235	1376	Science	HCAPLUS
Zylberberg, H	1996	23	1117	Clin Infect Dis	MEDLINE

L37 ANSWER 40 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:672955 HCAPLUS
DN 134:187861
TI Lack of interference between ribavirin and nucleosidic analogues in HIV/**HCV** co-infected individuals undergoing concomitant antiretroviral and anti-**HCV** combination therapy
AU Landau, Alain; Batisse, Dominique; Piketty, Christophe; Jian, Raymond; Kazatchkine, Michel D.
CS Service d'Hepatologie et de Gastro-Enterologie and Service d'Immunologie Clinique, Hopital Europeen Georges Pompidou, Universite Pierre et Marie Curie, Paris, Fr.
SO AIDS (London) (**2000**), 14(12), 1857-1858
CODEN: AIDSET; ISSN: 0269-9370

PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Changes in plasma HIV-RNA levels were examined during and after combination therapy with interferon-α (IFN) and ribavirin in 38 HIV/**hepatitis C virus** (**HCV**) coinfected patients. Nineteen of these patients had been treated with a combination of 2 nucleosidic analogs, stavudine and lamivudine or zidovudine and lamivudine for a mean duration of 20+/- 10 mo before the initiation of IFN and ribavirin. The remaining 19 patients had been treated with a triple combination antiretroviral regimen including a protease inhibitor with stavudine and lamivudine for 24 +/- 8 mo.. The mean plasma HIV-RNA levels did not differ between baseline (preadministration), at discontinuation of drug administration, and at 6 mo postadministration of IFN and ribavirin. The absolute number of CD4 cells decreased significantly during IFN treatment and returned to baseline values thereafter, suggesting that CD4 cells are trapped in extravascular sites during therapy with IFN. These results strongly argue against the in vivo relevance of the in vitro competition between ribavirin, stavudine, and zidovudine for intracellular phosphorylation. Ribavirin may thus be initiated in HIV/**HCV** coinfected patients receiving zidovudine or stavudine without switching reverse transcriptase inhibitors.
IT **3056-17-5**, Stavudine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(lack of interference between ribavirin and nucleosidic analogs in HIV/**HCV** co-infected individuals undergoing concomitant antiretroviral and anti-**HCV** combination therapy)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Benhamou, Y	1999	30	1054	Hepatology	MEDLINE
Darby, S	1997	350	1425	Lancet	MEDLINE
Ernstoff, M	1984	76	593	Am J Med	MEDLINE
Hoggard, P	1997	41	1231	Antimicrob Agents Ch	HCAPLUS
Landau, A	2000	14	839	AIDS	HCAPLUS
Poynard, T	1998	352	1426	Lancet	HCAPLUS
Soriano, V	1999	13	539	AIDS	MEDLINE
Zylberberg, H	1996	23	1117	Clin Infect Dis	MEDLINE

L37 ANSWER 41 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:573657 HCAPLUS
DN 133:172150
TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating **hepatitis** virus infections
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214 <--
	WO 2000047198	A3	20010215		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362914	AA	20000817	CA 2000-2362914	20000214 <--
	EP 1165080	A2	20020102	EP 2000-914585	20000214 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002536407	T2	20021029	JP 2000-598151	20000214 <--
	US 6545021	B1	20030408	US 2000-503945	20000214 <--
	EP 1658846	A1	20060524	EP 2005-27240	20000214 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 2003220299	A1	20031127	US 2003-341717	20030114 <--
PRAI	US 1999-119722P	P	19990212 <--		
	US 1999-119856P	P	19990212 <--		
	EP 2000-914585	A3	20000214 <--		
	US 2000-503945	A1	20000214 <--		
	WO 2000-US3768	W	20000214 <--		

OS MARPAT 133:172150
AB N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. are effective in treatment of **hepatitis** infections, including **hepatitis** B and **hepatitis C**. In treating **hepatitis** infections, the tittle compds. may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.
IT **3056-17-5**, Stavudine **7481-89-2**, Dideoxycytidine **147058-39-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(use of substituted dideoxyimino-D-glucitol compds. for treating **hepatitis** virus infections and combination with other antiviral agents or immunostimulants)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 147058-39-7 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L37 ANSWER 42 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:443717 HCAPLUS
DN 133:37763
TI Can **HCV** affect the efficacy of anti-HIV treatment?
AU Filippini, P.; Coppola, N.; Scolastico, C.; Liorre, G.; Nocera, R.; Sagnelli, E.; Piccinino, F.
CS Institute of Infectious Diseases, School of Medicine, Second University of Naples, Naples, Italy
SO Archives of Virology (**2000**), 145(5), 937-944
CODEN: ARVIDF; ISSN: 0304-8608
PB Springer-Verlag Wien
DT Journal
LA English
AB To evaluate the impact of new antiretroviral combinations (HAART: Highly Active Anti Retroviral Therapy) on **HCV** replication and liver enzyme levels, we analyzed the changes in **HCV** viremia and

aminotransferase levels in HIV and **HCV** co-infected patients. Moreover, to evaluate the influence of **HCV** infection on the efficacy of HAART, we compared the virol., immunol. and biochem. response to antiretroviral combinations in anti-HIV pos. subjects with or without **HCV** infection. We enrolled eight consecutive outpatients with HIV-**HCV** coinfection and with indications for HAART (Group A). For each patient in group A, we selected an anti-HIV neg. patient with indications for HAART, pair-matched for age, sex, risk factor for HIV infection, presumed duration of infection, number of CD4 cells, HIV viremia and treatment schedule (Group B). A statistically significant increase in CD4 in both groups was found at 1st, 3rd and 6th month of antiretroviral therapy. A decrease in HIV-RNA in both groups was observed at 1st and 6th month of treatment. The percentage of patients with undetectable HIV-RNA at the 1st month was higher in Group B than in Group A (8/8 vs. 3/8, p = 0.025). Basal **HCV**-RNA viremia was very high in each case and no variations during treatment were observed During therapy the aminotransferase levels slightly decreased in Group A and consistently increased in Group B. In Group A the differences were not significant to the statistical anal.; in Group B the aminotransferase levels at 3rd and 6th month were significantly higher than those observed at the baseline.

IT **3056-17-5**, Stavudine **7481-89-2**, Zalcitabine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(can **HCV** affect efficacy of anti-HIV treatment)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
BHIVA	1997	349	1086	Lancet	

Battegay, M	1996	24	961	Hepatology	MEDLINE
Brau, N	1997	349	924	Lancet	MEDLINE
Carpenter, C	1997	277	1962	JAMA	MEDLINE
Chamot, E	1992	6	430	AIDS	MEDLINE
Collier, A	1996	334	1011	N Engl J Med	HCAPLUS
Cribier, B	1995	9	1131	AIDS	HCAPLUS
Eyster, M	1994	84	1020	Blood	MEDLINE
Eyster, M	1993	6	602	J Acquir Immune Defi	MEDLINE
Francisci, D	1995	11	123	Eur J Epidemiol	MEDLINE
Hammer, S	1997	333	725	N Engl J Med	
John, M	1998	12	2289	AIDS	HCAPLUS
Markowitz, M	1995	333	1534	N Engl J Med	HCAPLUS
Matzuda, J	1997	350	364	Lancet	
Pantaleo, G	1996	50	825	Ann Rev Microbiol	HCAPLUS
Picard, O	1998	129	670	Ann Intern Med	MEDLINE
Rosado, R	1998	28	434A	Hepatology Supply	
Rutschmann, O	1998	177	783	J Infect Dis	HCAPLUS
Sabin, A	1997	175	164	J Infect Dis	
Sherman, K	1993	31	2679	J Clin Microbiol	MEDLINE
Soto, B	1997	26	1	J Hepatol	MEDLINE
Spengler, U	1998	29	1023	J Hepatol	MEDLINE
Thomas, D	1996	174	690	J Infect Dis	MEDLINE
Wrigh, T	1994	20	1152	Hepatology	
Zylberberg, H	1998	26	1104	Clin Infect Dis	MEDLINE

L37 ANSWER 43 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:401851 HCAPLUS
DN 133:53685
TI Protein transduction system and methods of use thereof
IN Dowdy, Steven F.
PA Washington University, USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000034308	A2	20000615	WO 1999-US29289	19991210 <--
	WO 2000034308	A3	20001019		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2354044	AA	20000615	CA 1999-2354044	19991210 <--
	AU 2000021728	A1	20000626	AU 2000-21728	19991210 <--
	EP 1137664	A2	20011004	EP 1999-966101	19991210 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002531113	T2	20020924	JP 2000-586751	19991210 <--
PRAI	US 1998-111701P	P	19981210 <--		
	WO 1999-US29289	W	19991210 <--		

OS MARPAT 133:53685
AB The present invention provides a protein transduction system comprising one or more fusion proteins that includes a transduction domain and a

cytotoxic domain. The cytotoxic domain is specifically activated in a cell exhibiting a unique characteristic. Further provided are protein transduction domains that provide enhanced transduction efficiency. The protein transduction system effectively kills or injures cells infected by one or a combination of different pathogens or cells exhibiting unique characteristics such as high levels of heavy metals, DNA damage or uncontrolled cell division.

IT **3056-17-5**, d4t **7481-89-2**, Ddc
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(protein transduction system and methods of use thereof)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 44 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:98300 HCAPLUS
DN 132:132356
TI Chemically induced intracellular hyperthermia for therapeutic and diagnostic use
IN Bachynsky, Nicholas; Roy, Woodie
PA Texas Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006143	A1	20000210	WO 1999-US16940	19990727 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2337690	AA	20000210	CA 1999-2337690	19990727	<--
AU 9951318	A1	20000221	AU 1999-51318	19990727	<--
AU 750313	B2	20020718			
EP 1098641	A1	20010516	EP 1999-935949	19990727	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRAI US 1998-94286P	P	19980727	<--	
WO 1999-US16940	W	19990727	<--	

AB Therapeutic pharmacol. agents and methods are disclosed for chemical induction of intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy, and other medical conditions. A process and composition are provided for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemical generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4-dinitrophenol, and their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

IT **3056-17-5 7481-89-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(chemical induced intracellular hyperthermia for diagnostic and therapeutic use, and use with other agents)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Gordon	1986			US 4569836 A	HCAPLUS
Gordon	1997			US 5622686 A	
Rubin	1991			US 5005588 A	

L37 ANSWER 45 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:566061 HCAPLUS
DN 131:170587
TI Preparation of 2'-fluoro nucleosides as antiviral agents
IN **Schinazi, Raymond F.**; Liotta, Dennis C.; Chu, Chung K.; Mcatee, J. Jeffrey; **Shi, Junxing**; Choi, Yongseok; Lee, Kyeong; Hong, Joon H.
PA Emory University, USA; The University of Georgia Research Foundation, Inc.
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943691	A1	19990902	WO 1999-US4051	19990225 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2322008	AA	19990902	CA 1999-2322008	19990225 <--
	AU 9927871	A1	19990915	AU 1999-27871	19990225 <--
	EP 1058686	A1	20001213	EP 1999-908437	19990225 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
	JP 2002504558	T2	20020212	JP 2000-533443	19990225 <--
	US 6348587	B1	20020219	US 1999-257130	19990225 <--
	BR 9908270	A	20040629	BR 1999-8270	19990225 <--
	US 2002198171	A1	20021226	US 2002-61128	20020130 <--
	US 6911424	B2	20050628		
	AU 2003244569	A1	20031002	AU 2003-244569	20030905 <--
	US 2004254141	A1	20041216	US 2004-796529	20040308 <--
PRAI	US 1998-75893P	P	19980225 <--		
	US 1998-80569P	P	19980403 <--		
	US 1999-257130	A1	19990225 <--		
	WO 1999-US4051	W	19990225 <--		
	US 2002-61128	A1	20020130 <--		

OS MARPAT 131:170587
GI



I

AB 2'-Fluoro nucleoside compds. I wherein R1 is OH, H, OR3, N3, CN, halogen, including F, or CF3, lower alkyl, amino, lower alkylamino, or alkoxy, and base refers to a purine or pyrimidine base; R2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo , is capable of providing a compound wherein R2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the Ph group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo , is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof, are disclosed which are useful in the treatment of **hepatitis** B infection, **hepatitis C** infection, HIV and abnormal cellular proliferation, including tumors and cancer. Thus, 1-(2,3-dideoxy-2-fluoro-β-L-glycero-pent-2-eno-furanosyl)thymine was prepared and tested for its antiviral activity (EC50 > 100 μM).

IT **221156-34-9P 222974-41-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fluoro nucleosides as antiviral agents and proliferation inhibitors)

RN 221156-34-9 HCAPLUS

CN Triphosphoric acid, P-[[(1R,4S)-4-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)-2-cyclopenten-1-yl]methyl] ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 222974-41-6 HCAPLUS

CN Triphosphoric acid, P-[[(1R,4S)-4-(4-amino-2-oxo-1(2H)-pyrimidinyl)-2-cyclopenten-1-yl]methyl] ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **221156-33-8P 221156-52-1P 221156-53-2P 221156-54-3P 238747-51-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fluoro nucleosides as antiviral agents and proliferation inhibitors)

RN 221156-33-8 HCAPLUS
CN 2(1H)-Pyrimidinone, 1-[(2R,4S)-4-[(acetyloxy)methyl]-2-cyclopenten-1-yl]-4-amino-5-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 221156-52-1 HCAPLUS
CN Acetamide, N-[1-[(2R,4S)-4-[(acetyloxy)methyl]-2-cyclopenten-1-yl]-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 221156-53-2 HCAPLUS
CN Acetamide, N-[1-[(2R,4S)-4-[(acetyloxy)methyl]-2-cyclopenten-1-yl]-1,2-dihydro-2-oxo-4-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 221156-54-3 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2R,4S)-4-(hydroxymethyl)-2-cyclopenten-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 238747-51-8 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(1R,4S)-4-(hydroxymethyl)-2-cyclopenten-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Claude, P	1996			US 5512671 A	HCAPLUS
Haru, M				EP 0839813 A	HCAPLUS
Haru, M	1997			WO 9737993 A	HCAPLUS
Siddiqui, M	1998	39	1657	TETRAHEDRON LETTERS	HCAPLUS
Sterzycki, R	1990	33	2150	JOURNAL OF MEDICINAL	HCAPLUS
Univ Emory	1996			WO 9622778 A	HCAPLUS
Univ Emory	1996			WO 9640164 A	HCAPLUS

L37 ANSWER 46 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:312073 HCAPLUS
DN 130:346921
TI Ritonavir and saquinavir combination therapy for the treatment of HIV infection
AU Cameron, D. William; Japour, Anthony J.; Xu, Yi; Hsu, Ann; Mellors, John;

Farthing, Charles; Cohen, Calvin; Poretz, Donald; Markowitz, Martin; Follansbee, Steve; Angel, Jonathan B.; McMahon, Deborah; Ho, David; Devanarayan, Viswanath; Rode, Richard; Salgo, Miklos P.; Kempf, Dale J.; Granneman, Richard; Leonard, John M.; Sun, Eugene
CS Ottawa General Hospital, Ottawa, ON, K1H 8L6, Can.
SO AIDS (London) (**1999**), 13(2), 213-224
CODEN: AIDSET; ISSN: 0269-9370
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB The safety and antiretroviral activity of ritonavir (NorvirTM) and saquinavir (InviraseTM) combination therapy were evaluated in patients with HIV infection. A group of 141 adults with HIV infection, CD4 T lymphocyte counts of 100-500 + 106 cells/l, whether treated previously or not with reverse transcriptase inhibitor therapy, but without previous HIV protease inhibitor drug therapy. After discontinuation of prior therapy for 2 wk, group I patients were randomized to receive either combination (A) ritonavir 400 mg and saquinavir 400 mg twice daily or (B) ritonavir 600 mg and saquinavir 400 mg twice daily. After an initial safety assessment of group I patients, group II patients were randomized to receive either (C) ritonavir 400 mg and saquinavir 400 mg three times daily or (D) ritonavir 600 mg and saquinavir 600 mg twice daily. Investigators were allowed to add up to two reverse transcriptase inhibitors (including at least one with which the patient had not been previously treated) to a patient's regimen after week 12 for failure to achieve or maintain an HIV RNA level ≤ 200 copies/mL documented on two consecutive occasions. Plasma HIV RNA levels and CD4+ T-lymphocyte counts were measured at baseline, every 2 wk for 2 mo, and monthly thereafter. Safety was assessed through the reporting of adverse events, phys. examns., and the monitoring of routine laboratory tests. The 48 wk of study treatment was completed by 75% (106/141) of the patients. Over 80% of the patients on treatment at week 48 had an HIV RNA level ≤ 200 copies/mL. In addition, intent-to-treat and on-treatment analyses revealed comparable results. Suppression of plasma HIV RNA levels was similar for all treatment arms (mean areas under the curve minus baseline through 48 wk were -1.9, -2.0, -1.6, -1.8 log10 copies/mL in ritonavir-saquinavir 400-400 mg twice daily, 600-400 mg twice daily, 400-400 mg three times daily, and 600-600 mg twice daily, resp.). Median CD4 T-lymphocyte count rose by 128 + 106 cells/l from baseline, with an interquartile range (IQR) of 82-221 + 106 cells/l. The most common adverse events were diarrhea, circumoral paresthesia, asthenia, and nausea. Reversible elevation of serum transaminases (> 5 + upper limit of normal) occurred in 10% (14/141) of the patients enrolled in this study and was associated with baseline abnormalities in liver function tests, baseline **hepatitis** B surface antigen positivity, or **hepatitis C** antibody positivity (relative risk, 5.0; 95% confidence interval 1.5-16.9). Most moderate or severe elevations in liver function tests occurred in patients treated with ritonavir-saquinavir 600-600 mg twice daily. Ritonavir 400 mg combined with saquinavir 400 mg twice daily with the selective addition of reverse transcriptase inhibitors was the best-tolerated regimen of four dose-ranging regimens and was equally as active as the higher dose combinations in HIV-pos. patients without previous protease inhibitor treatment.
IT **3056-17-5**, Stavudine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(antiviral activity of ritonavir and saquinavir combination therapy for

the treatment of human HIV infection with)
RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Buss, N	1998		145	5th Conference on Re	
Cameron, D	1998	351	543	Lancet	HCAPLUS
Carr, A	1997	349	996	Lancet	
Collier, A	1996	334	1011	N Engl J Med	HCAPLUS
Deeks, S	1997	277	145	JAMA	HCAPLUS
Gulick, R	1997	337	734	N Engl J Med	HCAPLUS
Hammer, S	1996	335	1081	N Engl J Med	HCAPLUS
Hammer, S	1997	337	725	N Engl J Med	HCAPLUS
Hsu, A	1998	63	453	Clin Pharmacol Ther	HCAPLUS
Jacobsen, H	1995	11	S169	AIDS Res Hum Retrovi	
Kempf, D	1998	12	F9	AIDS	HCAPLUS
Kempf, D	1997	41	654	Antimicrob Agents Ch	HCAPLUS
Kempf, D	1995	92	2484	Proc Natl Acad Sci U	HCAPLUS
Kohl, N	1988	85	4686	Proc Natl Acad Sci U	HCAPLUS
Lalezari, J	1996			XI International Con	
Marsh, K	1997	704	307	J Chromatogr	HCAPLUS
Merry, C	1997	11	F29	AIDS	HCAPLUS
Molla, A	1998	39	1	Antiviral Res	HCAPLUS
Molla, A	1996	2	760	Nat Med	HCAPLUS
Mulder, J	1994	32	292	J Clin Microbiol	HCAPLUS
National Institute Of A	1996			Division of AIDS: Di	
Peng, C	1989	63	2550	J Virol	HCAPLUS
Race, E	1998	351	252	Lancet	MEDLINE
Roberts, N	1990	248	358	Science	HCAPLUS
Roche Laboratories Inc	1998			Fortovase package in	
Roche Laboratories Inc	1998			Invirase package ins	
Rutschmann, O	1998	177	783	J Infect Dis	HCAPLUS
Seelmeier, S	1988	85	6612	Proc Natl Acad Sci U	HCAPLUS
Shapiro, J	1996	124	1039	Ann Int Med	

L37 ANSWER 47 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:484946 HCAPLUS
DN 129:121659
TI A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent
IN Michaels, Frank; Block, Timothy
PA Thomas Jefferson University, USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829121	A1	19980709	WO 1998-US4116	19980102 <--
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2276450	AA	19980709	CA 1998-2276450	19980102 <--
	EP 979080	A1	20000216	EP 1998-911458	19980102 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001507360	T2	20010605	JP 1998-530372	19980102 <--
	US 6355248	B1	20020312	US 1999-334819	19990617 <--
PRAI	US 1997-34596P	P	19970102 <--		
	WO 1998-US4116	W	19980102 <--		

AB Methods and compns. for modulating an immune response in mammals infected with a bacterium, a virus, or a parasite are provided. The methods and compns. are useful in mammals experiencing acute or chronic infections. The methods and compns. may be used in conjunction with known treatments for infection. The method entails the transmucosal administration of a composition comprising and epitope. The epitope of the mol. administered may be an epitope located on an antigen of the infectious agent or and epitope located on a tissue of the mammal. Typically, the tissue-derived epitope becomes reactive with the immune system and produces adverse or undesirable effects after the mammal is infected.

IT **7481-89-2**, Ddc
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(method of modulating an immune response in an infected mammal by transmucosal administration of epitopes and anti-infectious agents)

RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bolognesi	1995			US 5464933 A	HCAPLUS
Domb	1994			US 5340588 A	HCAPLUS
Hale	1997			US 5607691 A	HCAPLUS
Igari	1996			US 5482706 A	HCAPLUS
Marinaro, M	1995	155	4621	J Immunol	HCAPLUS
Yamagata	1997			US 5628993 A	HCAPLUS
Zhou, X	1991	75	117	Int J Pharm	HCAPLUS

L37 ANSWER 48 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:41720 HCAPLUS

DN 128:110885
TI Succinamic acid and succinimide derivatives having anti-inflammatory, anti-viral, and bronchodilating activity, preparation, compositions, and combinations with reverse transcriptase inhibitors
IN Hamedi-Sangsari, Farid; Nugier, Fabienne; Vallet, Thierry; Grange, Jacques; Vila, Jorge
PA Compagnie De Developpement Aguettant S.A., Fr.
SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 528,879.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5705522	A	19980106	US 1996-600525	19960213 <--
	CA 2231996	AA	19970320	CA 1996-2231996	19960913 <--
	WO 9710205	A1	19970320	WO 1996-IB942	19960913 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
	AU 9668350	A1	19970401	AU 1996-68350	19960913 <--
	EP 854860	A1	19980729	EP 1996-928647	19960913 <--
	EP 854860	B1	20010725		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000511871	T2	20000912	JP 1997-511797	19960913 <--
	AT 203513	E	20010815	AT 1996-928647	19960913 <--
PRAI	US 1995-528879	A2	19950915 <--		
	US 1996-600525	A	19960213 <--		
	WO 1996-IB942	W	19960913 <--		

OS MARPAT 128:110885
GI



I



II

AB A new family of compds. are provided having anti-inflammatory, anti-viral, and brochodilating activity. The compds are I and II [R1 = (halo-substituted) C1-4 alkyl; R2-R4 = H, (substituted) (branched) C1-8 alkyl, etc.]. Also provided are compns. of these compds., which alone, and in combination with reverse transcriptase inhibitors thereby resulting in an additive or synergistic effect, are useful in inhibiting or suppressing viruses including those exhibiting retroviral replication, or in treating viruses including a retrovirus such as HIV in a human cell population. Methods of using these compns., compds., and salts thereof are also provided. Preparation and anti-HIV activity of e.g. D-acetamido-N-hydroxysuccinamic acid are included.
IT **3056-17-5**, d4T **3416-05-5 7481-89-2**, DdC
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(succinamic acid and succinimide derivs. with antiinflammatory, antiviral, and bronchodilating activity, preparation, compns., and combinations with reverse transcriptase inhibitors)

RN 3056-17-5 HCAPLUS
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 3416-05-5 HCAPLUS
CN Thymidine, 3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1986			EP 0206497	HCAPLUS
Anon	1987			WO 8701284	HCAPLUS
Anon	1990			WO 9013291	HCAPLUS
Anon	1993			WO 9321218	HCAPLUS
Anon	1994			WO 9427590	HCAPLUS

Anon	1995			WO 9517875	HCAPLUS
Anon	1996			International Search	
Anon	1983			Merck Index 10, 8741	
Anon	1996			PCT/ISA/220 Notifica	
Barre-Sinoussi, F	1983	220	868	Science	MEDLINE
Blodgett	1985	107	4305	J Am Chem Soc	HCAPLUS
Blodgett	1985	107	4305	J Am Chem Soc	HCAPLUS
Bodansky, M	1984		125	The Practice of Pept	
Bukrinsky, M	1991	254	423	Science	HCAPLUS
Cdc	1981	30	305	MMWR	
Chow	1993	361	650	Nature	HCAPLUS
Fauci, A	1988	239	617	Science	MEDLINE
Fauci, A	1993	262	1011	Science	HCAPLUS
Fox, C	1991	164	1051	J Infect Dis	MEDLINE
Hirsch, M	1993	328	1686	New Engl J Med	MEDLINE
Lori	1994	266	801	Science	HCAPLUS
McMillan, R	1992	13	323	TIPS	HCAPLUS
Miller	1977	42	1750	J Org Chem	HCAPLUS
Mitsuya	1989			US 4861759	HCAPLUS
Mitsuya	1993			US 5254539	HCAPLUS
Pauwels, R	1988	20	309	J Virol Methods	HCAPLUS
Schnittman, S	1989	245	305	Science	MEDLINE
Vila	1996			US 5571839	HCAPLUS
Vogel	1957	371	375	Text-Book of Practic	
Yarchoan	1989	321	726	New Engl J Med	HCAPLUS
Zack, J	1990	61	213	Cell	MEDLINE

L37 ANSWER 49 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:810659 HCAPLUS
DN 123:208840
TI Hepatocyte-targeted drug conjugates
IN Plourde, Robert, Jr.; Carmichael, Ellen; Spitalny, George L.; Findeis, Mark A.; Ernst, Michael F.; Robinson, Brett
PA Targetech, Inc., USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9518636	A2	19950713	WO 1995-US448	19950111 <--
	WO 9518636	A3	19950810		
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2180348	AA	19950713	CA 1995-2180348	19950111 <--
	AU 9516791	A1	19950801	AU 1995-16791	19950111 <--
	EP 737077	A1	19961016	EP 1995-908490	19950111 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09510696	T2	19971028	JP 1995-518699	19950111 <--
PRAI	US 1994-180207	A	19940111 <--		
	WO 1995-US448	W	19950111 <--		

AB The invention provides conjugates for targeting a therapeutic agent to a cell with asialoglycoprotein receptors. The conjugates comprise a therapeutic agent and ligand for the asialoglycoprotein receptor, wherein

the therapeutic agent and the ligand are linked by a bridging agent. The bridging agent can be a crosslinker, a polyfunctional carrier mol. or a crosslinker and a polyfunctional carrier mol. In a preferred embodiment, the therapeutic agent is a nucleoside analog or colchicine and the ligand is asialoorosomucoid, arabinogalactan or a tris-(N-acetyl galactosamine aminohexyl glycoside) amide of tyrosyl(glutamyl)-glutamate. Preferred crosslinkers include aminoacyl derivs., carboxyacyl derivs., phosphate, peptides and reductively-labile crosslinkers. Preferred polyfunctional carrier mols. include polyamino acids and polysaccharides. The conjugates of the invention can be used to target a therapeutic agent to a cell, for example to inhibit viral DNA replication in a virally-infected hepatocyte.

IT **7481-89-2DP**, reaction products with polyaldehyde dextran, conjugates with asialoorosomucoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrugs for drug targeting to asialoglycoprotein receptors of hepatocytes)
RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **7481-89-2**, 2',3'-Dideoxycytidine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prodrugs for drug targeting to asialoglycoprotein receptors of hepatocytes)
RN 7481-89-2 HCAPLUS
CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L37 ANSWER 50 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
AN **1994:23538** HCAPLUS
DN 120:23538
TI Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
IN Blough, Herbert A.
PA U.S. Bioscience, Inc., USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318763	A1	19930930	WO 1993-US2432	19930318 <--
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5491135	A	19960213	US 1993-32234	19930317 <--
	AU 9339659	A1	19931021	AU 1993-39659	19930318 <--
	EP 660710	A1	19950705	EP 1993-909132	19930318 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07507770	T2	19950831	JP 1993-516700	19930318 <--
	BR 9306123	A	19970826	BR 1993-6123	19930318 <--
PRAI	US 1992-853454	A	19920318 <--		
	US 1993-32234	A	19930317 <--		
	WO 1993-US2432	A	19930318 <--		

AB Antiviral compns. are described which contain the title compound and ≥1 other antiviral agent which act synergistically or additively.

IT **151779-22-5**
RL: BIOL (Biological study)
(as virucide)

RN 151779-22-5 HCAPLUS

CN L-Aspartic acid, N-(phosphonoacetyl)-, mixt. with 2',3'-dideoxycytidine (9CI) (CA INDEX NAME)

CM 1

CRN 51321-79-0
CMF C6 H10 N O8 P

Absolute stereochemistry.



CM 2

CRN 7481-89-2
CMF C9 H13 N3 O3

Absolute stereochemistry. Rotation (+).